Rodman & Renshaw Annual Global Investment Conference Presenter Profiles

Rodman & Renshaw Annual Global Investment Conference Presenter Profiles

Company: 4SC AG Ticker Symbol & Exchange: VSC / Xetra Investor Relations Contact: Bettina von Klitzing Investor Relations Contact Phone: 49-89-700 763 0 Web: www.4sc.com Date of Presentation: November 10th, 2008

4SC AG develops innovative drug candidates against inflammatory diseases and cancer. 4SC AG utilises its proprietary technology platform, to create a sustainable project pipeline of drug candidates, which are to be developed up to clinical proof of concept in early clinical phases. There are currently eight projects in development. A clinical phase IIa for the treatment of rheumatoid arthritis has already successfully been completed. An additional

project for the treatment of various cancers is currently completing a clinical phase I trial. The company is listed at the Prime Standard of Frankfurt Stock Exchange since December 2005.

Company: Aastrom Biosciences, Inc. Ticker Symbol & Exchange: NASDAQ: ASTM Investor Relations Contact: Kris M. Maly/Kimberli O'Meara Investor Relations Contact Phone: (734) 930-5777 Web: www.aastrom.com Date of Presentation: 11/11/2008; 5:20 PM-5:45 PM

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. Aastrom's Tissue Repair Cell (TRC) based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. The Company is currently focused on cardiovascular regeneration and is conducting a Phase II clinical trial with

dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial).

Company: Access Pharmaceuticals, Inc. Ticker Symbol & Exchange: ACCP.OB Investor Relations Contact: Stephen B. Thompson Investor Relations Contact Phone: 214-905-5100 Web: www.accesspharma.com Date of Presentation: Tuesday, November 11, 2008

Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, MuGard(TM) for the management of oral mucositis that is partnered globally, and should commence sales in 4Q08. The company's lead oncology product is ProLindac(TM), a polymer-linked platinum cancer drug, which is in Phase 2 clinical

testing in recurrent ovarian cancer patients. AngiolixÂŽ an antiangiogenic humanized monoclonal antibody, and Thiarabine, a novel nucleoside in trials in leukemia, are the company's lead oncology products. Access is also developing oral insulin and oral hGH using its proprietary Cobalamin(TM) oral drug delivery technology.

Company: Action Energy Inc. Ticker Symbol & Exchange: AEC - TSX-V Investor Relations Contact: Mr. Kelly D. Kerr - VP Finance Investor Relations Contact Phone: (403) 723-4454 Web: www.action-energy.com Date of Presentation: 11/10/2008

Action Energy Inc. is a Calgary Alberta based junior oil and natural gas exploration company focused on exploring the western Canadian sedimentary basin for properties with significant production and reserve potential. Action was incorporated in 2000 and to date has quickly grown to a company producing 1,500 -

1,600 boed through a combination of exploration and development drilling and mergers and acquisitions.

The Company has a portfolio mainly consisting of light oil properties focused on the Bakken and Midale plays in southeast Saskatchewan, heavy oil in the Lloydminster area of central Alberta and sweet natural gas properties in the Peace River Arch area of northwest Alberta. Action has captured large concentrated undeveloped land positions with high working interests in its primary plays giving the Company large upside potential.

Company: Active Biotech AB Ticker Symbol & Exchange: ACTI; OMX Nordic Investor Relations Contact: Mr Gรถran Forsberg Investor Relations Contact Phone: +46 46 19 11 54 Web: www.activebiotech.com Date of Presentation: 11/11/2008

Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a

biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer.

Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDexÂŽ for RA. Please visit www.activebiotech.com for more information.

Company: Acucela Inc. Investor Relations Contact: Sayuri Refsland Investor Relations Contact Phone: 425-527-3272 Web: www.acucela.com Date of Presentation: 11/12/2008

Acucela Inc. is a clinical-stage biotechnology company focused on developing new drug therapies for blinding eye diseases such as age-related macular degeneration (AMD), Stargardt disease, diabetic retinopathy and retinopathy of prematurity, as well as dry eye. The

most advanced product candidate of our developing compounds, Rebamipide ophthalmic suspension, is currently in Phase III clinical trials for dry eye and is being co-developed with Otsuka Pharmaceutical in the U.S. We are also conducting a Phase I clinical trial of ACU-4429 for dry age-related macular degeneration (AMD), which is also being co-developed with Otsuka Pharmaceutical.

Company: Adanac Molybdenum Corporation Ticker Symbol & Exchange: AUA & Frankfurt A9N Investor Relations Contact: Connie Fischer/Peter Jones Investor Relations Contact Phone: 604.531.9639 or 604.535.6834 Web: www.adanacmoly.com Date of Presentation: 11/11/2008

Adanac Molybdenum Corporation is listed on the TSX and Frankfurt exchanges and owns the Ruby Creek Molybdenum Project in Northern British Columbia. The Company has advanced the project through feasibility studies, a production decision and has previously ordered $137 million of long-lead equipment, completed permitting

for construction, constructed a road to the site and secured US$80 million in bridge financing. The Company is sourcing final construction funding and expects a site construction start in February 2009 and production in Q4, 2010. The mine will be the world's first new large scale molybdenum open pit mine in more than 25 years.

Company: AgFeed Industries, Inc. Ticker Symbol & Exchange: FEED (NASDAQ) Investor Relations Contact: Mr. Gerry Daignault Investor Relations Contact Phone: 615-480-7847 Web: www.agfeedinc.com Date of Presentation: 11/10/2008 9:55 AM

AgFeed Industries, Inc. a US public company is the largest commercial hog producer and the largest premix feed company in China. With over 600 million hogs produced each year, compared to 100 million in the US, China represents more than 50% of the world's annual hog production as well as the world's largest and most profitable pork consumer markets. We are a strategic platform for

accessing China's vast feed and hog raising industries. The pre-mix feed market in which AgFeed operates is an approximately $1.6 billion segment of China's $40 billion per year animal feed market.

Company: Alberta Oilsands Inc. Ticker Symbol & Exchange: AOS Web: www.aboilsands.ca Date of Presentation: November 12, 2008 at 10:20am

Alberta Oilsands Inc. (TSX-V: AOS) is a junior oil sands development company focused in the Athabasca oil sands region of northeast Alberta. The Company has acquired 89,920 gross (77,568 net) acres of prospective oil sands leases on the primary oil sands fairway.

AOS's strategy is to take advantage of its proven oil sands experience to delineate and prove up bitumen reserves sufficient to support a minimum 10,000 barrel per day in-situ project by 2012.

The company has four project areas, namely Clearwater, Hangingstone, Algar lake and Grand rapids which in aggregate hold nearly 5 billion barrels of bitumen in place. The Clearwater delineation drilling

program in Q1-2009 provided the company with 320 million barrels of contingent recoverable bitumen resource over just 2800 acres and potentially two 10,000 barrels per day projects

Company: Alhambra Resources Ltd. Ticker Symbol & Exchange: ALH - TSX Venture Investor Relations Contact: Ihor P. Wasylkiw Investor Relations Contact Phone: 1 (403) 508-4953 Web: www.alhambraresources.com Date of Presentation: Tuesday, Nov 11/08 @ 2:50 PM EST

Alhambra is a Canadian based international exploration and gold production Corporation, celebrating its 7th year of operations in the Republic of Kazakhstan. Alhambra holds exploration and exploitation rights to a 2.7 million acre, 100% owned, property called the Uzboy Project, located in the prolific Charsk Gold Belt which hosts numerous world-class gold deposits. Alhambra is currently producing gold and has 14 years remaining of a 25 year license which is renewable for an additional 20 years and allows the

Corporation to explore for all metals including gold, base metals, uranium and molybdenum.

Company: Allon Therapeutics Inc. Ticker Symbol & Exchange: TSX:NPC Investor Relations Contact: Aaron Keay Investor Relations Contact Phone: Cell: (604) 323-6911, D: (604) 742-2540 Web: www.allontherapeutics.com Date of Presentation: Monday, November 10, 2008 - 9:30am ET

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's lead clinical program is focused on Alzheimer's disease. In February 2008 the Company announced positive results in a Phase IIa clinical study for amnestic MCI, a precursor to Alzheimer's disease, showing statistically significant, dose dependant, and durable efficacy on human memory. The Company also has a Phase II trial underway in schizophrenia cognitive impairment.

The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company) and based in Vancouver.

Company: Allos Therapeutics, Inc. Ticker Symbol & Exchange: NASDAQ: ALTH Investor Relations Contact: Derek Cole Investor Relations Contact Phone: 720.540.5367 Web: www.allos.com Date of Presentation: Tuesday, November 11, 2008

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company expects to report top line results of the PROPEL trial by the end of 2008. The Company

is also investigating PDX in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma subtypes. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma (NHL). Allos currently retains exclusive worldwide rights to PDX and RH1.

Company: Alphatec Spine Ticker Symbol & Exchange: ATEC Investor Relations Contact: Cheryl Monblatt Investor Relations Contact Phone: 760 494 6746 Web: www.alphatecspine.com Date of Presentation: Monday, November 10

Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative,

surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, The Company also markets its spine products in Europe.

Company: Amarin Corporation Ticker Symbol & Exchange: AMRN (Nasdaq) Investor Relations Contact: Darren Cunningham Investor Relations Contact Phone: 35316699020 Web: www.amarincorp.com Date of Presentation: 11/11/08

Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease.

Company: American Lorain Corporation Ticker Symbol & Exchange: ALRC.OB Investor Relations Contact: CCG Investor Relations Investor Relations Contact Phone: Crocker Coulson, 646-213-1915 Web: www.lorainfood.com Date of Presentation: November 10th at 3:15 pm ET

American Lorain Corp. is a major processed foods company located in China. The Company commenced operations of Shandong Lorain, its first operating subsidiary, in 1995, to manufacture chestnut products and over years, it expanded its product lines to include canned, frozen and bulk foods, and convenience foods sold to domestic and international customers. The Company now has four manufacturing facilities. In the highly fragmented processed foods industry, Lorain has gained competitive advantages through its proprietary brands and advanced technologies and currently sells over 192 products to19 provinces and administrative regions in China as well as to 42 foreign countries.

Company: American Tony Pharmaceuticals Inc Ticker Symbol & Exchange: OTC BB/ATNY.OB Investor Relations Contact: Leslie Wolf-Creutzfeldt Investor Relations Contact Phone: 646-284-9472 Web: www.tmyy.com.cn Date of Presentation: Nov 12 at 9:30am

Tongli Pharmaceutical (USA), Inc. develops, manufactures and markets pharmaceutical and health care products through its wholly-owned subsidiary, Harbin Tianmu Pharmaceutical Co., Ltd. ("Tianmu Pharmaceutical"). Tianmu Pharmaceutical was founded in 1999 in Harbin, hub of the Northern Pharmaceutical base of China. The company acquired the GMP certificate in 2003 and was listed on the OTC Bulletin Board on July 29, 2008. With a cohesive management team and committed staff, Tongli is providing the best quality pharmaceutical products at a very competitive price. The company is targeting the vast Chinese market with a vision of extending its footprint to East Asia and Russia.

Company: Anadis Limited Ticker Symbol & Exchange: ASX: ANX Investor Relations Contact: Dr. Oren Fuerst Investor Relations Contact Phone: 646 259 3321 Web: www.anadis.com Date of Presentation: 11/12/2008

Anadis is a biopharmaceutical company focused on antigen-primed, dairy-derived health products. Anadis' proprietary and low-cost antibody manufacturing technology enables it to rapidly develop polyclonal antibody and other protein-based oral therapies to a range of important infectious and immunemediated diseases.

Large target markets with products reaching the markets in 2-3 years, all using the same platform. o Cancer therapy-related Mucositis (clinical trial in Israel started)

o HIV/AIDS (major clinical trial in Australia just announced) o Diabetes (clinical trial to be initiated within a few months pending a transaction) o Influenza (clinical trial to begin during the year) Commercial products : E.coliTravelers' Diarrhea and Rotavirus infection

Company: Argentex Mining Corporation Ticker Symbol & Exchange: TSX-V:ATX;OTCBB:AGXM Investor Relations Contact: Primoris Group Inc. Investor Relations Contact Phone: 1-866-594-7687 Web: www.argentexmining.com Date of Presentation: Tues. November 11, 2008, 11:10 a.m.

Argentex Mining Corporation is a junior mining exploration company with extensive holdings in Argentina's Patagonia region, including its flagship Pinguino property in Santa Cruz province. The company

holds 100% mineral rights to this property, which has a unique commodity profile: gold, silver, lead, zinc and indium. Argentex's exploration team has taken Pinguino from the grassroots stage to a significant drill-tested deposit (30,000+ meters completed) in just a few years. Argentex also owns 100% mineral rights to more than 30 properties with over 377,490 acres (152,766 hectares) of prospective land located in Argentina's Santa Cruz and Rio Negro provinces.

Company: Arrow Energy Limited Ticker Symbol & Exchange: AOE.AX (ASX) Investor Relations Contact: Graham Yerbury Investor Relations Contact Phone: +61 7 31053466 Web: www.arrowenergy.com.au Date of Presentation: Monday November 10, 2008

Arrow Energy is an ASX 100 listed Coal Bed Methane Company operating in Australia and South East Asia. Arrow's Australian tenements are estimated to have 70Tcf of gas in place. Arrow and it's joint

venture partner Shell are moving towards developing the world's first CBM to LNG operation in the Gladstone port with initial plans for a 1.5mtpa plant in operation by 2012. Arrow has also integrated downstream into the production of electricity with access to 370MW of electricity offtake. Arrow is currently completing exploration and appraisal activity in India and Vietnam with business development opportunities in China and Indonesia.

Company: Asia Time Corporation Ticker Symbol & Exchange: Amex: TYM Investor Relations Contact: Brandi Floberg Investor Relations Contact Phone: 310-277-4711 Web: www.asiatimecorp.com Date of Presentation: November 10, 2008 at 10:20 a.m. ET

Asia Time is a Hong Kong distributor of timepiece movements. The Company currently distributes approximately 350 products, including both watch movements and complete watches, representing 30 vendors.

These products are supplied to Asia Time's

more than 300 customer manufacturers of globally branded watches.

The Company's distribution centers and sales offices are located throughout Hong Kong and China.

Asia Time is well positioned to capitalize on growth opportunities in developed markets and especially in the under-penetrated market for watch movements and completed watches in China. The Company holds strong competitive advantages in quartz and mechanical movements, and it seeks to expand up the watch market value chain into low-cost China-based manufacturing of proprietary branded movements and complete watches.

Company: Aurora Oil & Gas Limited Ticker Symbol & Exchange: "AUT" on ASX Investor Relations Contact: Jon Stewart (Exec Chairman) Investor Relations Contact Phone: admin@auroraoag.com.au, 61 89440 2626 Web: www.auroraoag.com.au Date of Presentation: 11/10/2008

Aurora Oil & Gas Limited is an Australian quoted public company (ASX: AUT) focused in North America. Aurora participates in advanced exploration/development opportunities with large size potential.

Aurora's principal asset is its substantial landholdings in the recently discovered Sugarkane Field in South Texas. Sugarkane Field is a potential multi TCFe gas and condensate resource.

The Sugarkane Field was discovered in 2006 with an exploration well that intersected a unique over pressured, porous condensate rich Austin Chalk formation within the region. Several follow up wells have been successfully drilled and appraisal and development drilling of this field is under way.

Company: Ausam Energy Corporation Ticker Symbol & Exchange: AZE.V, ASMEF.OB Investor Relations Contact: Mark G. Avery Investor Relations Contact Phone: 1.863.678.2200 Web: www.ausamenergy.com

Date of Presentation: 11/11/2008

Ausam is a public company engaged in oil and gas exploration and development. Ausam, through its U.S. subsidiary Noram Resources, Inc, has acquired a diverse portfolio of oil and gas leases and prospects in Texas, Louisiana, Mississippi, Alabama and Arkansas.

Ausam's growth strategy includes the systematic development of its current holdings and selective corporate transactions. The Company trades under the symbol "AZE" on the TSX Venture Exchange and the symbol "ASMEF" on the OTC Bulletin Board

Company: Avanir Pharmaceuticals Ticker Symbol & Exchange: AVNR / NASDAQ Investor Relations Contact: Eric Benevich Investor Relations Contact Phone: (949)389-6776 Web: www.avanir.com Date of Presentation: November 11, 2008 at 4:55pm ET

AVANIR Pharmaceuticals is a biopharmaceutical company focused on developing novel treatments for central nervous system conditions.

AVANIR's lead product candidate, Zenvia(TM), is in Phase III development for two indications; pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. Zenvia is the subject of an approvable letter from the FDA for the PBA indication.

The Company is now conducting a confirmatory Phase III study testing a lower dose formulation intended to improve safety and tolerability. Top line results are expected in Q3 of 2009. Please review AVANIR's SEC filings or www.avanir.com for further information regarding risks and uncertainties affecting the Company.

Company: Bio-Bridge Science, Inc. Ticker Symbol & Exchange: BGES - OTCBB Investor Relations Contact: Chris Young Investor Relations Contact Phone: (630) 928-0869 Web: http://www.bio-bridge-science.com Date of Presentation: 11/12/2008

Bio-Bridge Science is a biotechnology company engaged in the commercial development of vaccines and related products for the prevention and treatment of human diseases. The company is currently developing oral vaccines against HIV, HPV and colon cancer. In addition, the Company has a subsidiary that produces bovine serum and plans to form a joint venture to produce cell culture medium for vaccine production.

Company: BioDelivery Sciences International Ticker Symbol & Exchange: BDSI (NASDAQ) Investor Relations Contact: Bryan Armstrong Investor Relations Contact Phone: 312-553-6707 Web: bryan.armstrong@fdashtonpartners.com Date of Presentation: Mon. November 10, 2008 at 10:20 am

BioDelivery Sciences is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships, new applications of proven therapeutics.

The development strategy focuses on the utilization of the FDA's 505(b)(2) approval process to obtain timely and efficient approval of new formulations of previously approved therapeutics which incorporate the company's drug delivery technologies, BioErodible MucoAdhesive (BEMA) and Bioral.

BDSI is addressing important unmet market needs with a focus on formulations of pharmaceuticals aimed principally at treatment opportunities in areas such as pain and fungal infections. The company's lead product ONSOLIS (BEMA Fentanyl) is currently under review at FDA with an anticipated approval 1H 2009.

Company: BioSante Pharmaceuticals, Inc. Ticker Symbol & Exchange: BPAX NASDAQ Investor Relations Contact: Phillip Donenberg Investor Relations Contact Phone: 847-478-0500 ext 100 Web: www.biosantepharma.com Date of Presentation: 11/12/2008

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGelÂŽ (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology.

Company: Boots & Coots Ticker Symbol & Exchange: NYSE Alternext: WEL Investor Relations Contact: Jennifer Tweeton Investor Relations Contact Phone: 281-931-8884 Web: www.boots-coots.com

Date of Presentation: November 11, 10:45 am Eastern

Boots & Coots provides a suite of integrated pressure control services to oil and gas exploration companies around the world. Our services are designed to enhance production and reduce the number and severity of critical well events such as well fires, blowouts or other losses of control at the well. Our Well Intervention segment includes services performed by hydraulic workover and snubbing units and the rental of pressure control tools. This segment also includes prevention and risk management services offered through our Safeguard and risk mitigation programs. Our Response segment consists of personnel, equipment and services provided during a critical well event.

Company: BPZ Energy Ticker Symbol & Exchange: NYSE Alternext:BPZ Investor Relations Contact: Greg Smith Investor Relations Contact Phone: 281 752 1240 Web: www.bpzenergy.com

Date of Presentation: 11/10/2008

Houston based BPZ Energy is an oil and gas exploration and production company which has exclusive license contracts for oil and gas exploration and production covering approximately 2.4 million acres in four properties in northwest Peru. It also owns a minority working interest in a producing property in southwest Ecuador. The Company is currently executing the development of the Corvina oil discovery, the redevelopment of the Albacora oil field, and the exploration of Block XIX, in parallel with the execution of an integrated gas-to-power strategy, which includes generation and sale of electric power in Peru and the development of a regional gas marketing strategy. The Company's website at www.bpzenergy.com provides additional information about the Company's plans, including photographs and other information with respect to its operat

Company: Bradmer Pharmaceuticals Inc. Ticker Symbol & Exchange: BMR (TSX) Investor Relations Contact: Ross Marshall, Equicom Group Investor Relations Contact Phone:

416-815-0700 x238 Web: http://www.bradmerpharma.com Date of Presentation: 11/12/08, 10:45 a.m.

Bradmer Pharmaceuticals is a biopharmaceutical company established in 2006 to advance a promising new drug for glioblastoma multiforme patients into a pivotal Phase III trial. Neuradiab(TM) (formerly referred to as "I-131 mu81C6" in scientific literature) is a radiolabeled monoclonal antibody that has been delivered to more than 200 patients in its significant Phase I and II clinical history at Duke University. It has been designed to deliver a precise localized radiation boost dose specifically to post-surgical residual cancer cells via single injection. Our multi-center randomized trial for patients with newly-diagnosed GBM is underway at leading brain tumor treatment centers across the US. This Phase III trial will investigate Neuradiab as an adjuvant therapy to surgery, external beam radiation and temozolomide.

Company: Bravo Venture Group Inc. Ticker Symbol & Exchange: BVG-TSX.Venture

Investor Relations Contact: Jay Oness Investor Relations Contact Phone: 1-888-456-1112/604-641-2771 Web: www.bravoventuregroup.com Date of Presentation: Tuesday, November 11th at 2:25pm

The company is active in NW British Columbia, Alaska and Nevada. The VMS/Epithermal gold/silver Homestake Ridge project in BC is advancing with excellent drill results and an NI43-101 compliant technical report (being updated) which reported an inferred resource of +900,000 oz/Au. Recent certified assays from the now completed 8,400 metre drill program returned BONANZA grade intercepts;73metres averaging 21g/t gold with an intercept of 7.65metres averaging 181.58 g/t gold, as well, another intercept recorded 22.29metres of 513.7 g/t silver including a 2.71metre bonanza grade averaging 2,502 g/t silver.

Other project include the VMS Woewodski Island project in Alaska and 13 projects in Nevada.

Company: CanAlaska Uranium Ltd

Ticker Symbol & Exchange: TSX.V: CVV Investor Relations Contact: Emil Fung, V.P. Corp. Dev. Investor Relations Contact Phone: 604 688 3211 Web: www.canalaska.com Date of Presentation: Tuesday, November 11th 2008 @ 14:00

CANALASKA URANIUM LTD. (CVV -- TSX.V) is undertaking uranium exploration in nineteen 100%-owned and two optioned uranium projects in Canada's Athabasca Basin, supplier of 30% of the world's uranium and home to the planet's richest uranium mines. Since September 2004, the Company has aggressively acquired one of the largest land positions in the region, comprising over 2,500,000 acres (10,117 sq. km or 3,906 sq. miles). To-date, CanAlaska has expended over Cdn$45 million and has delineated multiple uranium targets. The company is financially-supported by numerous strategic partners, including, Mitsubishi Development Pty, a subsidiary of Japanese conglomerate Mitsubishi Corporation, and a consortium of leading Korean energy companies comprising Hanwha Corp., KEPCO, KORES and SK Energy.

Company:

Candax Energy Inc. Ticker Symbol & Exchange: CAX: TSX Investor Relations Contact: Lindsay Carpenter Investor Relations Contact Phone: lindsay@chfir.com, 416-868-1079 ext. 239 Web: www.candax.com Date of Presentation: 11/11/2008

Candax Energy Inc. is a Canadian based oil and natural gas company engaged in the exploration, acquisition, development and production of crude oil and natural gas, with emphasis on Africa and the Middle East. Candax has three producing fields in Tunisia: offshore at El Bibane, and onshore at Ezzaouia and Robbana and significant upside potential through its Deep Triassic play, its onshore Chaal gas discovery and its promising early exploration work in Madagascar. Candax's net production for Q3 is expected to average 1,600 boepd (1,200 bopd and 2 MMcf/d) and production for Q4 is forecast at 2,800 boepd (2,000 bopd and 4.7 MMcf/d).

Company: CAS Medical Systems, Inc.

Ticker Symbol & Exchange: CASM Investor Relations Contact: Susan Carron Investor Relations Contact Phone: 203-488-6056 Web: www.casmed.com Date of Presentation: 11/12/2008

CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.

The Company's product lines also include bedside patient vital signs monitors, proprietary non-invasive blood pressure measurement technology, blood pressure cuffs and products for neonatal intensive care.

Company: Cavico Corp.

Ticker Symbol & Exchange: OTCBB: CVIC Investor Relations Contact: Roger Ellis Investor Relations Contact Phone: Tel: 310-477-9800 Ext 106 Web: www.cavicocorp.com Date of Presentation: 11/11/2008

Cavico Corp. is a major infrastructure contractor with over 3,000 employees, including 700 engineers. Headquartered in Hanoi, Vietnam, Cavico operates nationwide in Vietnam with an expanding global presence through direct and indirect subsidiaries. Cavico is the only firm using the latest Tunnel Boring Machine (TBM) Technology in Vietnam. As an essential participant in the development of Vietnam's infrastrcuture to support Asia's second highest growth rate, Cavico has a focus on large construction projects for hydropower facilities, dams, bridges, tunnels, roads, and mines. Cavico also participates in ownership investments related to its core competency in energy, mining, cement plants, and urban development companies.

Company: Celsion Corporation Ticker Symbol & Exchange: NASDAQ: CLSN Investor Relations Contact: Geoffrey Grande, CFA Investor Relations Contact Phone: 617-747-1721 Web: http://www.celsion.com/ Date of Presentation: Nov. 11th, from 4:30 to 4:55 PM

Celsion Corporation is an oncology drug development company focused on addressing cancers of high unmet medical needs. The proprietary drug platform - heat activated liposomal technology - effectively targets high concentrations of chemotherapeutics to organs of interest. The lead drug candidate - ThermoDox is currently in global Phase III trials for liver cancer in 7 countries. Additional drug candidates liposomal docetaxel and liposomal carboplatin are currently in preclinical development. Celsion has research, license or commercialization agreements with leading institutions such as the NIH-NCI, Philips, Duke, University of Hong Kong,

Cleveland Clinic, North Shore-LIJ, and 40 other leading medical institutions worldwide.

Company: China Armco Metals, Inc. Ticker Symbol & Exchange: OTC BB: CNAM Investor Relations Contact: HC International, Inc. Investor Relations Contact Phone: Alan Sheinwald, 914-669-5340 Web: www.armcometal.com Date of Presentation: 11/10/2008

China Armco Metals, Inc. imports, sells, distributes metal ores and non-ferrous metals throughout the PRC. Armco is also ennted into the metal recycling business. The Company's product lines include ferrous and non-ferrious ore such as iron ore, chrome ore, nickel ore, copper ore, magnese ore and steel billet. Raw materials are supplied from global suppliers in India, Hong Kong, Nigeria, Brazil, Turkey, the Philippines and Libya. Beginning in the second quarter 2009, Armco expects to begin operations in its steel recycling and scrap metal supply. The recycling facility is

expected to be capable of recycling one million metric tons of scrap metal per year which will position the Company as one of the top 10 recyclers of scrap metal in China.

Company: China Direct, Inc. Ticker Symbol & Exchange: NASDAQ: CDS Investor Relations Contact: Lillian Wong Investor Relations Contact Phone: 954.363.7333 ext. 317 Web: www.ChinaDirectInc.com Date of Presentation: 11/10/2008

China Direct is a diversified management and advisory services organization which owns and consults business entities operating in the People's Republic of China. We operate two divisions: Management Services and Advisory Services.

Our Management Services division acquires controlling interests of Chinese business entities. Our Advisory Services division provides consulting services to both Chinese entities seeking access to the U.S. capital markets and North American entities seeking business

opportunities in the PRC. As a direct link to China, China Direct serves as a vehicle allowing investors to participate directly in the rapid growth of the Chinese economy. For more information, please visit www.ChinaDirectInc.com.

Company: China Green Agriculture Inc. Ticker Symbol & Exchange: CGAG.OB Investor Relations Contact: Ying Yang Investor Relations Contact Phone: 626-623-2575 Web: www.cgagri.com Date of Presentation: 11/12/2008

China Green Agriculture, through its wholly-owned subsidiary Shaanxi TechTeam Jinong Humic Acid Product Co., Ltd, develops, manufactures and distributes humic acid-based liquid compound fertilizers in 27 provinces throughout China. The Company offers over 100 different varieties of fertilizers targeted to unique climate and soil specifications. China Green Agriculture's headquarters, based in Shaanxi Province, include extensive R&D

facilities and cutting edge automated production lines. With one of the most recognizable brand names in Chinese green fertilizers today, the Company is one of the few fertilizer manufacturers in China that operates on a national scale.

Company: China Marine Food Group, Ltd. Ticker Symbol & Exchange: OTC BB: CMFO Investor Relations Contact: HC International, Inc. Investor Relations Contact Phone: John Mattio, 914-669-5340 Web: www.china-marine.cn Date of Presentation: 11/10/2008

Founded in 1994, China Marine Food Group, Ltd. processes and distributes processed seafood snack-type products, fresh and frozen marine catch to five provinces in the PRC and select international markets. Since inception, China Marine has grown steadily, received "The Famous Brand" and "Green Food" awards, and positioned its "Mingxiang"brand as a category leader in 1,300 retail sales points in the PRC. The Company is committed to the

highest standard of quality control and is strategically located in Fujian Province, one of the largest coastal provinces in the PRC and a vital navigation hub bewteen the East China Sea and the South China Sea. For the first six months ended June 30, 2008, revenue and net income increased 35.9% and 39.2% to $23.8 million and $6.0 million respectively.

Company: China North East Petroleum Holdings Ltd. Ticker Symbol & Exchange: CNEH OTCBB Investor Relations Contact: Chao Jiang Investor Relations Contact Phone: 212-307-3568 Web: www.cnepetroleum.com Date of Presentation: 11/12/2008

China North East Petroleum Holdings Limited (OTCBB: CNEH), through its subsidiaries, engages in the extraction and production of crude oil in Northern China. The company was founded in 2002 and is based in Harbin China and New York. The company owns 20 years leasing rights in Jilin Qian'an Oil Field, an oil field located

approximately 9 kilometers southwest of Qian'an city Jilin Province China with a total exploration area of approximately 11,663 acres.

The Company has a guaranteed arrangement with the Jilin Refinery of PetroChina to sell its produced crude oil for use in the China marketplace. China North East Petroleum currently has about 312 employees and 214 wells within four oilfields in Northern China and has plans for additional well drilling projects.

Company: China Wind Systems, Inc. Ticker Symbol & Exchange: CWSI.OB Investor Relations Contact: Crocker Coulson Investor Relations Contact Phone: (646) 213-1915 Date of Presentation: 4:05 p.m. 11th November 2008

China Wind Systems, Inc. supplies forged rolled rings to the wind power and other industries and industrial equipment to the textile and energy industries in China. With its newly finished state-of-the-art production facility, the Company is expected soon to significantly increase its shipment of high- precision rolled rings and other essential components primarily to the wind power and

other industries.

Company: China Yingxia International, Inc. Ticker Symbol & Exchange: CYXI.OB Investor Relations Contact: CCG Investor Relations Investor Relations Contact Phone: Crocker Coulson, 646-213-1915 Web: www.chinayingxia.com Date of Presentation: November 12th at 10:45 am

China Yingxia International, Inc. is primarily engaged in the development, production and sales of health food products in China.

The Company sells over 235 stock keeping units (SKUs) in five product categories including soybean-based food and drinks, Longgu golden millet enriched products, raw cacti, cactus-based herbal supplements, personal care products, Nestle products and organic rice products. Yingxia was founded in 1998 and is headquartered in Harbin, Heilongjiang province, People's Republic of China.

Company: ChinaCast Education Corporation Ticker Symbol & Exchange: CAST - NASDAQ Investor Relations Contact: Michael Santos Investor Relations Contact Phone: 202-361-3403 Web: www.chinacasteducation.com Date of Presentation: Nov. 10, 2008

ChinaCast Educations Corporation is a leading for-profit, post-secondary education and e-learning services provider in China.

We provide fully accredited four year degree and two year diploma post-secondary education programs through our university in Chongqing, the Foreign Trade and Business College (FTBC) of Chongqing Normal University. We provide our e-learning services to post-secondary institutions, K-12 schools, government agencies and corporations via our nationwide satellite broadband network. These services include interactive distance learning applications, multimedia education content delivery, English language training and vocational training courses.

Company: Cipher Pharmaceuticals Inc. Ticker Symbol & Exchange: DND: TSX Investor Relations Contact: Craig Armitage Investor Relations Contact Phone: (416) 815-0700 x278 Web: www.cipherpharma.com Date of Presentation: 11/12/2008

Cipher Pharmaceuticals is an emerging specialty pharmaceutical company with a late-stage product portfolio. The Company is focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies.

Cipher's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America (formerly ProEthic Pharmaceuticals) under the label LipofenÂŽ.

In addition, Cipher is developing novel formulations of the pain reliever tramadol and the acne treatment isotretinoin.

Company: Clinuvel Pharmaceuticals Limited Ticker Symbol & Exchange: ASX: CUV, ADR: CLVLY Investor Relations Contact: Colin Mackie Investor Relations Contact Phone: 61 3 9660 4900 Web: www.clinuvel.com Date of Presentation: November 12, 2008 - 3:15PM Louis Rm

Clinuvel Pharmaceuticals Limited (Clinuvel) is an Australian biopharmaceutical company developing a first-in-class photoprotective drug afamelanotide* (CUV1647) for use in a range of UV and light related skin disorders.

Afamelanotide provides skin protection against UV radiation (UVR) as it stimulates the body's natural ability to produce eumelanin, the dark pigment of the skin which is known to have photoprotective properties.

Clinuvel has identified five indications and has two Phase III

trials underway, aswell as three Phase II trials. Clinuvel aims to have afamelanotide in the market by 2010.

Company: Comanche Clean Energy Corp.

Ticker Symbol & Exchange: OTCBB:CGYYF Investor Relations Contact: Todd M. Pitcher Investor Relations Contact Phone: 760-798-4938 Web: www.comanchecleanenergy.com Date of Presentation: November 10 at 10:20AM

Comanche Clean Energy is a Brazil-based producer of ethanol and biodiesel from multiple feed-stocks in its own facilities and grows the majority of the sugar-cane feedstock that it requires for producing ethanol, creating a vertically integrated model. The company's customers for ethanol are fuel distributors and trading companies and its current biodiesel sales are to Petrobras, the Brazilian oil company. Comanche owns and operates two ethanol facilities and one biodiesel facility in Brazil. Through the six months ended, June 30, 2008, revenues were $22.1 million, up from

$1.1 million reported for the same period last year.

Company: CombinatoRx, Incorporated Ticker Symbol & Exchange: CRXX Investor Relations Contact: Gina Nugent Investor Relations Contact Phone: 617-301-7099 Web: www.combinatorx.com Date of Presentation: Nov. 10, 2008

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel

drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts.

Company: Cougar Biotechnology, Inc. Ticker Symbol & Exchange: NASDAQ: CGRB Investor Relations Contact: Mariann Ohanesian Investor Relations Contact Phone: 310-943-8040 Web: www.cougarbiotechnology.com Date of Presentation: 11/12/2008

Cougar Biotechnology is a development stage biopharmaceutical company based in Los Angeles, California that in-licenses novel therapeutics and develops such therapeutics for the treatment of cancer. Our strategy is to license technologies that have previously been tested in clinical trials, enabling us to obtain an initial indication of the drug's safety and biological activity in humans before committing capital to the drug's development.

Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in a Phase III clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Company: CPEX Pharmaceuticals, Inc. Ticker Symbol & Exchange: NASDAQ : CPEX Investor Relations Contact: Laura Okpala Investor Relations Contact Phone: 617-583-1306, lokpala@troutgroup.com Web: www.cpexpharm.com Date of Presentation: Tuesday November 11, 2008 2:30PM

CPEX Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company primarily focused on the development of Nasulin(TM), an intranasal insulin drug, currently in Phase II trials for diabetes. CPEX has a proprietary drug delivery platform

technology, CPE-215ÂŽ, which allows it to expand its internal pipeline of products beyond Nasulin and generate revenue from partnering. CPEX has licensed applications of CPE-215 to Auxilium Pharmaceuticals, which launched TestimÂŽ in 2003. CPEX received royalties of $11.1 million in 2007 from sales of Testim. In addition, CPEX has a partnership with Serenity Pharmaceuticals for the development of a urology product incorporating its CPE-215 platform technology.

Company: Crosshair Exploration & Mining Corp Ticker Symbol & Exchange: CXZ:AMEX, CXX:TSX Investor Relations Contact: Jennifer Richards Investor Relations Contact Phone: 604-681-8030 x.229 Web: www.crosshairexploration.com Date of Presentation: 11/12/2008 12:25

Crosshair is a leading junior exploration company focused on exploring and developing uranium in the Central Mineral Belt of Labrador, which is fast emerging as the next big uranium district in

Canada.

Crosshair is demonstrating the multi-deposit potential of the project by successfully developing and drilling several new uranium targets and currently controls four existing NI 43-101 compliant resources.

Crosshair's gold and Volcanic Hosted Massive Sulphide projects in Newfoundland, are slated for a dividend spin-out to shareholders. Crosshair currently trades on the Toronto Stock Exchange (CXX:TSX) and the American Stock Exchange (CXZ:AMEX).

Company: Cue Energy Resources Limited Ticker Symbol & Exchange: ASX : CUE Investor Relations Contact: Pauline Moffatt Investor Relations Contact Phone: 61 3 9670 8668 Web: www.cuenrg.com.au Date of Presentation: 11/11/2008

Cue is a small Australian independent, SE Asia and Australasian focussed, oil and gas exploration and production company. Cue has current oil production in Papua New Guinea and Indonesia with additional oil production beginning in New Zealand in late 2008. Gas production is expected to begin in Indonesia in 2009 and 2010.

Appraisal drilling on other gas and oil discoveries is expected in 2009.

Cue also holds a balanced portfolio of exploration areas in Australia, Papua New Guinea, New Zealand and Indonesia in which there are ongoing seismic and exploration drilling programs, and has interests in approximately 280 net BCF of contingent gas resources in Australia and Papua New Guinea.

Company: Cyclacel Pharmaceuticals, Inc. Ticker Symbol & Exchange: CYCC - NASDAQ Investor Relations Contact: Corey Sohmer Investor Relations Contact Phone: 908-517-7330 Web: www.cyclacel.com Date of Presentation:

11/12/2008

Cyclacel is a biopharmaceutical business dedicated to discovery, development and commercialization of novel, targeted drugs to treat cancer and other serious disorders. Three orally-available drugs are in clinical development: sapacitabine, in randomized Phase 2 studies for the treatment of elderly acute myeloid leukemia, myelodysplastic syndromes and cutaneous T-cell lymphoma; seliciclib, in randomized Phase 2 studies for the treatment of non-small cell lung and nasopharyngeal cancers; and CYC116, in Phase 1 for solid tumors.

Cyclacel's ALIGN subsidiary sells three products in the US treating the effects of radiation or chemotherapy in cancer patients: XclairÂŽ Cream, Numoisyn(TM) Liquid and Lozenges.

Company: Cytomedix Ticker Symbol & Exchange: AMEX:GTF Investor Relations Contact: Enrique Briz Investor Relations Contact Phone: 212/888-4848 Web: http://www.cytomedix.com Date of Presentation:

Wednesday, Nov. 12, 2008 (2:25 pm)

Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, including the AutoloGel(TM) System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood. The AutoloGel(TM) System is cleared by the Food and Drug Administration ("FDA") for use on a variety of exuding wounds. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel(TM) System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide, that has shown promise in pre-clinical testing, and for which the Company is currently preparing an Investigational New Drug (IND) application for the FDA.

Company: Deer Consumer Products, Inc. Ticker Symbol & Exchange: DCPI (OTC BB) Investor Relations Contact: Ms. Yong MeiWang Investor Relations Contact Phone: 86 755-86028285

Web: www.deerinc.com Date of Presentation: 11/10/2008 14:25

Deer Consumer Products, Inc. is a US public company headquartered in China. Supported by more than 75 patents, Deer is a market leader in the design, manufacture and sale of home and kitchen electronics targeting the vast Chinese domestic consumer markets as well as customers in more than 40 countries worldwide. Deer's product lines include blenders, juicers, pressure cookers and other home electronics designed to improve home lifestyles in today's fast paced society. With more than 100 global and domestic clients including Black & Decker, Disney, Toastmaster, Home Depot and Wal-Mart, Deer has enjoyed rapid sales and earnings growth.

Company: Delcath Systems, Inc. Ticker Symbol & Exchange: DCTH NASDAQ Investor Relations Contact: Strategic Growth International Investor Relations Contact Phone: Richard Cooper, 212.838.1444 Web:

www.delcath.com Date of Presentation: 11/11/2008

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents worldwide, including the U.S., Europe, Asia and Canada.

Company: Derma Sciences Inc Ticker Symbol & Exchange: DSCI OTCBB Investor Relations Contact: Rudy Barrio @ Allen&Caron Inc Investor Relations Contact Phone: 212 691 8087 Web:

www.dermasciences.com Date of Presentation: Wednesday, November 12, 2008 @ 2:00

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in 2008.

Company: DOR BioPharma, Inc. Ticker Symbol & Exchange: DORB: OTCBB Investor Relations Contact: Evan Myrianthopoulos Investor Relations Contact Phone:

609-538-8200 Web: www.dorbiopharma.com Date of Presentation: 11/10/2008

DOR BioPharma is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBecÂŽ (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. DOR anticipates market potential for orBecÂŽ for the treatment of GI GVHD to be approximately 60% of the more than 10,000 allogeneic hematopoietic cell transplantations that occur each year in the US, with similar numbers in Europe.

Company: ECU Silver Mining Inc. Ticker Symbol & Exchange: TSX: ECU Investor Relations Contact:

Christopher Haldane Investor Relations Contact Phone: 416.868.1079 ex.237 Web: www.ecu.ca Date of Presentation: 11/10/2008

ECU Silver Mining Inc. is focused on the exploration, development and mining of gold, silver and base metals at its VelardeĂąa District Properties in Durango, Mexico. The district is well known for its mining history and ECU holds three properties that include five historical mines. ECU has measured and indicated resources of 38 million ounces and inferred resources of 179 million ounces of silver equivalent. ECU's goal is to establish a significant polymetallic mineral resource in the heart of Mexico's mining district. Our mission is to become a pre-eminent silver and gold producer through the development of existing, and additional potential resources at VelardeĂąa.

Company: eFuture Information Technology Ticker Symbol & Exchange: Nasdaq:EFUT

Investor Relations Contact: Troe Wen Investor Relations Contact Phone: 86 1051650988 Web: www.e-future.com.cn Date of Presentation: 11/11/2008

eFuture Information Technology Inc. (NASDAQ: EFUT) is a leading provider of front-end supply chain management software and services in China. eFuture provides integrated software and services to manufacturers, distributors, wholesalers, logistics companies and retailers in China's front-end supply chain market, especially in the retail and FMCG industries. eFuture serves over 1,000 clients, including 15 Fortune 500 companies, over 900 retailers and over 200 distributors in China. eFuture is one of IBM's premier business partners in Asia Pacific and also partners with Oracle, Microsoft, JDA, Motorola and Samsung Network China. eFuture has over 600 employees and 20 branch offices across China.

Company: Enable Holdings, Inc Ticker Symbol & Exchange:

ENAB Investor Relations Contact: Ryan Calverley Investor Relations Contact Phone: 773.272.4414, Ryan.Calverley@enableholdings.com Web: www.EnableHoldings.com Date of Presentation: 11/10/2008

Enable Holdings Inc., is the world's leading excess inventory solutions company that links brand name sellers with customers around the globe. Enable Holdings, Inc. does this through its unique multi-channel asset-recovery solution that includes online auction platform solution uBid.com, fixed-price commerce solution RedTag.com, offline excess inventory solution RedTag Live!, business-to-business solution Dibu Trading Company, and private auction software solution Commerce Innovations. Brand name sellers are able to reduce distressed and excess inventories more efficiently and profitably than ever before, and achieve greater yield, while providing shoppers a connection to the world's most trusted brands at a value.

Company: Endocyte, Inc.

Investor Relations Contact: Vickey Buskirk Investor Relations Contact Phone: 765-463-7175 Web: www.endocyte.com Date of Presentation: 11/10/2008

Great progress has been made in the development of new drugs to treat cancer and other serious illness. However, these therapies are often administered at suboptimal doses because of their side effects on healthy tissues. The value of these therapies is further diminished because of the inability to predict if a patient will respond to a particular therapy. Endocyte is addressing both of these issues using a new "drug guidance" technology that is designed to deliver drugs directly to diseased cells. This guidance system is composed of a targeting ligand that attaches to a drug and then binds to receptors over-expressed on the membranes of diseased cells.

Company: Energy Fuels, Inc. Ticker Symbol & Exchange: TSX: EFR Investor Relations Contact:

Gary Steele Investor Relations Contact Phone: 303-974-2147 Web: www.energyfuels.com Date of Presentation: 11/11/2008

Energy Fuels is pursuing a mission to build a fully integrated uranium and vanadium production company through exploration, development, mining, milling & sales. The Company is a conventional, underground miner, utilizing low risk techniques of drilling, split shooting, and diesel haulage of waste and ore to the surface.

Current technology is applied wherever it will increase productivity, lower cost, and improve grade control. Primary activities include:

o Developer and miner of southwest US U3O8 and V2O5 properties o Prudent property acquisition to maintain full pipeline for production o Property interests include six formerly producing U mines o Aggressively refurbishing two of those mines to return them to production o Licensing the 1000 tpd PiĂąon

Ridge U/V mill, the first US mill for processing U to be built in 25 years

Company: Epic Energy Resources Ticker Symbol & Exchange: EPCC - OTC BB Investor Relations Contact: Lisa Elliott Investor Relations Contact Phone: 713- 529-6600, lelliott@drg-e.com Web: www.1epic.com Date of Presentation: 11/11/2008

EPiC Energy Resources is a Houston based integrated energy services company. EPiC provides consulting, engineering, construction management, operations, maintenance, specialized training and data management services focused primarily on the upstream and midstream energy infrastructure. Services are provided through Pearl, a diversified engineering and energy services company; Carnrite, a management consulting company focused on providing strategic and operational consulting services to the broad energy industry; and EIS, a global training and data management services company. Epic's

Pearl operations oversee projects primarily in the Rockies and has ongoing projects in the Middle East. Unconventional gas exploration and oil discoveries in the Rocky Mountains and other markets in the U.S. has driven strong demand for its services.

Company: Evolution Petroleum Ticker Symbol & Exchange: EPM - AMEX Investor Relations Contact: Lisa Elliott Investor Relations Contact Phone: 713-529-6600, lelliott@drg-e.com Web: evolutionpetroleum.com Date of Presentation: 11/11/2008

Evolution Petroleum Corporation acquires known, onshore oil and gas resources and applies conventional and specialized technology to accelerate production and develop incremental reserves and value.

With no debt and a strong balance sheet, the Company is well positioned to carry out its initiatives.

Principal assets include 4 MMBOE of proved and 3.1 MMBOE of probable

reserves in the Giddings Field of central Texas, more than 13 MMBO of probable reserves associated with the 13,636 acre Delhi Field Holt Bryant Unit currently being redeveloped with CO2-EOR technology in northeast Louisiana, and leases covering approximately 18,000 net acres in two Woodford gas shale projects in Oklahoma. The Company is also actively engaged in developing new projects within its initiatives.

Company: First Majestic Silver Corp.

Ticker Symbol & Exchange: TSX. - FR Investor Relations Contact: Dan McIntyre/Jill Arias Investor Relations Contact Phone: 6046883033 Web: www.firstmajestic.com Date of Presentation: Monday, November 10th. 2:50pm

First Majestic Silver Corp. is a pure silver producing mining company focused in Mexico. The Company strives for continued growth with a proven aggressive growth strategy based on the development of its existing assets and acquisition of advance staged silver

projects that meet its growth profile.

This past year the Company focused on an extensive mine development campaign at each of its three operating silver mines in Mexico; the La Parrilla, the La Encantada, and the San Martin Silver Mines.

Approximately, 90% of the Company's overall revenue is from the sale of silver. For the year ending 2007, First Majestic's produced 3.6 million ounces compared to 1.6 million in 2006. In addition, at the year ended 2007, 164 million ounces of NI 43-101 compliant silver equivalent resources had been defined, compared to approximately 70 million

Company: Fronteer Development Group Ticker Symbol & Exchange: TSX/AMEX: FRG Investor Relations Contact: Richard Moritz Investor Relations Contact Phone: 1.877.632.4677 (TF/North America) Web: www.fronteergroup.com Date of Presentation: Monday, Nov. 10, 2008, 3:15 p.m.

Fronteer's vision is to become a multibillion-dollar, gold-growth company advancing a pipeline of projects from exploration through to production. Fronteer has an interest in several major gold projects in Nevada and Turkey. The company's Nevada projects include Northumberland, one of the largest undeveloped Carlin-style gold deposits; Long Canyon, a discovery defining a new gold trend; and, Sandman, a property Newmont Mining Corp. has the option of advancing to a production decision within 36 months. In Turkey, Fronteer has a 40% interest in a new mineral district that includes two gold deposits and a copper-gold porphyry deposit. Fronteer has no debt and holds approximately C$85 million in cash that is fully liquid and held with a large Canadian bank.

Company: FX Energy, Inc. Ticker Symbol & Exchange: FXEN Investor Relations Contact: Scott Duncan Investor Relations Contact Phone: 801 486-5555 Web: www.fxenergy.com

Date of Presentation: 11/11/2008

We are an independent oil and gas exploration and production company headquartered in Salt Lake City, Utah. Our principal production, reserves, and exploration activities are in Poland, although we have a modest oil presence in the U.S. We hold 3.7 million gross acres (3.2 million net) in Poland. We believe Poland represents a unique international exploration opportunity. Relatively little gas has been discovered in Poland's sector of the North European Permian Basin, compared to the discoveries in the United Kingdom, Dutch, and German sectors. Consequently, we think the Polish Permian Basin is underexplored and underexploited.

Company: Gastar Exploration Ltd. Ticker Symbol & Exchange: AMEX:GST/TSX:YGA Investor Relations Contact: Michael Gerlich Investor Relations Contact Phone: 713-739-1800 Web: www.gastar.com Date of Presentation:

11/12/2008

Gastar has significant acreage in the Deep Bossier Sands play in East Texas, the developing Marcellus Shale play in Appalachia, the Powder River Basin, and the Gunnedah Basin of southeastern Australia. In East Texas, Gastar controls approximately 15,350 net acres in Leon and Robertson counties. Since 2003, Gastar has successfully completed 16 Bossier and five Knowles wells. We are currently running a two-rig program to drill offsets to recent successful Bossier wells. In Australia, coalbed methane development programs are under way on 2.1 million net acres to supply developing gas markets in New South Wales. In Appalachia, we are pursuing development of shale gas beneath approximately 42,000 net acres of leases in West Virginia and Pennsylvania near acreage held by the most active participants in the play.

Company: Genco Resources Ltd. Ticker Symbol & Exchange: TSX: GGC Investor Relations Contact: Ms. Jada Soomer Investor Relations Contact Phone: (604) 682-2205 Web:

www.gencoresources.com Date of Presentation: 430pm - 455pm November 10th

Genco Resources Ltd. is a publicly-traded mining company focused on developing its La Guitarra silver property in Mexico.

Genco's core asset, the producing La Guitarra silver-gold mine, is located in the Temascaltepec Mining District of Mexico. La Guitarra Mine currently consists of two underground operation centres - La Guitarra and San Raphael - and a flotation mill with a proven capacity of 320 tonnes per day. Genco believes significant potential exists to expand production within the 39,714 hectares of mining concessions it currently owns or leases in the Temascaltepec Mining District.

Genco aims to create solid shareholder value through continued growth and increased production.

Company: Glass Earth Gold Ltd Ticker Symbol & Exchange: GEL: TSXV Investor Relations Contact:

Lindsay Carpenter Investor Relations Contact Phone: lindsay@chfir.com, 416-868-1079 ext. 239 Web: www.glassearthlimited.com Date of Presentation: 11/11/2008

Glass Earth is a New Zealand based gold explorer with the largest on-shore gold exploration permit portfolio (over 22,000 square kilometers). Glass Earth's strategy is to apply sophisticated use of new technology, over entire geological provinces permissive for large gold deposits. Glass Earth is now at the target specific drilling stage in 3 regions: Hauraki; Mamaku and Otago. Glass Earth's strategy for 2008/2009 is to continue work on high priority targets, building towards 43 101 compliant resources. Glass Earth has over $2.2 million cash and 3 contributory joint ventures, including 2 with Newmont over the Hauraki Region and an area next to Newmont's Martha Gold Mine.

Company: Gold Horse International, Inc. Ticker Symbol & Exchange: GHII

Investor Relations Contact: Adam Wasserman Investor Relations Contact Phone: (800)867-0078 Ext. 702 Date of Presentation: 3:15 p.m. 12th November 2008

Gold Horse International, Inc., through its wholly owned subsidiaries, Gold Horse International, Inc. (Nevada) and Global Rise International Ltd., controls and operates Inner Mongolia Jin Ma Construction Co., Ltd., Inner Mongolia Jin Ma Hotel Co., Ltd., and Inner Mongolia Jin Ma Real Estate Development Co., Ltd., all based in Hohhot, the regional capital of Inner Mongolia Autonomous Region in China. Jin Ma Construction has been providing construction and general contractor services in Hohhot to both private developers and to the local and regional governments since 1980. Jin Ma Hotel owns, operates and manages the Jin Ma Hotel, a full-service, two-star hotel located in Hohhot. Jin Ma Real Estate develops residential and commercial properties in Hohhot.

Company: GTC Biotherapeutics Ticker Symbol & Exchange: GTCB Investor Relations Contact:

Thomas Newberry Investor Relations Contact Phone: 508-370-5374 Web: www.gtc-bio.com Date of Presentation: 11/11/2008

GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology.

ATrynÂŽ, GTC's recombinant human antithrombin, has been approved for use in Europe and is being reviewed in the United States under a Biologics License Application. In addition to ATrynÂŽ, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 as well as to CD137. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes.

Company: Gulf Resources, Inc.

Ticker Symbol & Exchange: GFRE.OB Investor Relations Contact: Crocker Coulson Investor Relations Contact Phone: 646-213-1915 Web: www.gulfresourcesco.com Date of Presentation: 10:45AM, ET, November 10, 2008

Gulf Resources, Inc. is a leading provider of chemical products in the People's Republic of China. The Company operates through its two wholly-owned subsidiaries; Shouguang City Haoyuan Chemical Company Limited (SCHC), which primarily produces and distributes bromine and crude salt, and Shouguang Yuxin Chemical Industry Co., Limited (SYCI), which focuses on manufacturing and selling chemical products. Elemental bromine is used to manufacture a wide range of compounds utilized in manufacturing industries and in agriculture. The Company's chemical products are utilized in a variety of applications, including oil and gas field exploration, and as papermaking chemical agents.

Company:

Hollis-Eden Pharmaceuticals, Inc. Ticker Symbol & Exchange: NASDAQ: HEPH Investor Relations Contact: Scott A. Rieger Investor Relations Contact Phone: 858-587-9333 Web: www.holliseden.com Date of Presentation: 11/10/2008

Hollis-Eden Pharmaceuticals is developing a proprietary new class of small molecule compounds that are metabolites or synthetic analogs of adrenal steroid hormones. The Company's clinical drug development candidates include TRIOLEX(TM) (HE3286), currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and APOPTONE(TM) (HE3235), in a clinical trial for late-stage prostate cancer. In addition to these drug candidates, designed to restore the biological activity of cellular signaling pathways disrupted by disease and aging, Hollis-Eden has an active research program generating additional compounds that are being evaluated in preclinical models of a number of diseases.

Company: Hong Kong Highpower Technology, Inc. Ticker Symbol & Exchange: Amex: HPJ Investor Relations Contact: Brandi Floberg Investor Relations Contact Phone: 310-277-4711 Web: http://www.haopengbattery.com/ Date of Presentation: November 12, 2008 at 2:00 p.m. ET

Hong Kong Highpower Technology is a profitable growth company that develops, manufactures and markets nickel-metal hydride (Ni-MH) and lithium-ion (Li-ion) rechargeable batteries and related products for consumer and industrial applications. The Company's products are distributed worldwide for use in various electronic products and emergency power supplies such as digital and communication products, power tools, toys, notebook computers, cell phones, GPS navigation systems, military products, electronic bikes and medical devices. The Company's manufacturing and product development facilities are located in Shenzhen, Guangdong Province, PRC, which facilitates low labor costs and easy access to land and raw materials, as well as additional cost and cycle time advantages garnered by proximity to electronics

supply chains and end-markets.

Company: Horizon Therapeutics Investor Relations Contact: Bob DeVaere Investor Relations Contact Phone: 760-436-4010 Web: www.horizontherapeutics.com Date of Presentation: 11/12/2008

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance.

Horizon's lead compound is HZT-501, a novel, proprietary, fixed-dose combination formulation of the world's most prescribed non-steroidal anti-inflammatory drug (NSAID), ibuprofen, with a high dose of the most potent H2 antagonist, famotidine (Pepcid), in a single pillwhich

For more information about the company and its products, please visit www.horizontherapeutics.com.

Company: Hudson Technologies Ticker Symbol & Exchange: HDSN; NASDAQ Investor Relations Contact Phone: John Nesbett, 203-972-9200 Web: www.hudsontech.com Date of Presentation: 11/10/2008

Hudson Technologies is a leading provider of refrigerants and the largest reclaimer in the U.S. for commercial refrigeration and air conditioning systems. In addition to its refrigerant sales and reclamation business, Hudson also provides energy optimization of large steam and refrigeration systems as well as energy efficiency assessments. The company's two revenue streams are:

Refrigerant Product Services (RPS), comprised of refrigerant sales and reclamation of refrigerants, such as CFCs, HCFCs and replacement refrigerants used in commercial air conditioning and refrigeration systems.

RefrigerantSideÂŽ Services (R-SideÂŽ) identifies and provides predictive and emergency solutions for mechanical and chemical issues in large process and comfort cooling systems.

Company: Hythiam, Inc. Ticker Symbol & Exchange: HYTM/NASDAQ Investor Relations Contact: Hasmik Bulujian Investor Relations Contact Phone: hbulujian@hythiam.com, 310-444-4333 Web: www.hythiam.com Date of Presentation: Monday, November 10, 2008

Hythiam provides through its Catasys offering, behavioral health management services to health plans, employers and unions through licensed and company managed healthcare providers. Catasys offers integrated substance dependence solutions built around the patented PROMETA Treatment Program for alcoholism and stimulant dependence. PROMETA, which integrates behavioral, nutritional, and

medical components, is also available on a private-pay basis through licensed treatment providers and company managed treatment centers. Hythiam researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Hythiam does not manufacture, distribute, or sell any medications and has no relationship with any manufacturers/distributors of medications used in the PROMETA Treatment Program.

Company: ICP Solar Technologies Ticker Symbol & Exchange: OTC BB: ICPR Investor Relations Contact: Chris Witty Investor Relations Contact Phone: 646-438-9385 Web: www.ICPSolar.com Date of Presentation: 11/10/2008

ICP Solar is a developer, manufacturer and marketer of solar panels, solar cell based products, solar monitoring software and solar power management solutions. Through the application of its own

intellectual property and next-generation technologies, the Company aims to be the solar industry's innovation leader. For the past 20 years, ICP Solar has been a lead innovator in the consumer solar market and has now begun to apply that same innovation philosophy to the OEM, rooftop and power generation segment of the solar industry.

ICP Solar's management has over 50 years of experience in the renewable energy sector. ICP Solar markets its products under its SunseiÂŽ brand of solar products and is the North American licensee of the ColemanÂŽ brand in the solar charger category.

Company: ImmunoCellular Therapeutics Ticker Symbol & Exchange: OTCBB:IMUC Investor Relations Contact: Jennifer Cook Williams Investor Relations Contact Phone: 360-668-3701 Web: www.imuc.com Date of Presentation: 11/11/2008

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage

company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate--a dendritic cell-based vaccine for treating brain tumors--is currently being evaluated in a Phase I clinical trial. The company's "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials during the first half of 2009. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer.

Company: ImmuneRegen BioSciences, Inc Ticker Symbol & Exchange: IRBS OTCBB Investor Relations Contact: John Fermanis Investor Relations Contact Phone: 480-322-3926 Web: www.immuneregen.com Date of Presentation: November 10, 2008 12:25pm

ImmuneRegen BioSciences, Inc. (OTCBB: IRBS) is a development-stage

biotechnology company focused on the research, development and licensing of HomsperaÂŽ, an adult stem cell active peptide that regenerates and strengthens the immune system and enhances wound healing. Homspera's ability to enhance adult stem cell activity in bone marrow underlies the successful animal studies we've reported previously for the compound in the areas of protection from lethal radiation, treating neutropenia, vaccine adjuvancy, infectious disease (both alone and in combination) and wound healing. We've forged numerous partnerships with both industry and academic leaders as we progress toward IND filing planned for mid-2009.

Company: Industrea Limited Ticker Symbol & Exchange: ASX: IDL Investor Relations Contact: Jennifer K. Zimmons, Ph.D. Investor Relations Contact Phone: 212-838-1444 Web: www.industrea.com.au Date of Presentation: Tuesday, Nov. 11, 2008 9:55am

Industrea Limited (ASX: IDL) manufactures, sells and supports market-leading mining products globally and provides integrated contract-mining services. Industrea's business provides diversified revenue streams arising from mining, asset management, and engineering services. The Company's geographical footprint includes: Australia, United States, South America, Indonesia, New Guinea, Russia, and China. Major customers include: BHP, Anglo Coal, Rio Tinto and Xstrata. Industrea continues to expand its markets, range of products and services, and customers to increase the Company's sources of revenue. Current mining products include: collision-avoidance systems, underground directional-drilling, above-ground directional drilling, contractor management, mobile-asset tracking and driver-safety performance index.

Company: InNexus Biotechnology Inc. Ticker Symbol & Exchange: (TSX: IXS.V) (IXSBF.OB) Investor Relations Contact: Jeff Morhet Investor Relations Contact Phone: 480-862-7500 Web:

www.ixsbio.com Date of Presentation: November 11, 2008 at 12:00 p.m.

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications.

In a short period of time, InNexus has assembled facilities, resources, a stellar Scientific Advisory Board, staff and milestones yielding multiple pre-clinical candidates targeting cancer and other commercial opportunities. InNexus has launched into pre-clinical development its first four products, DXL625 and DXLr120, both for the prospective treatment of non-Hodgkin's lymphoma and other immune disorders that include rheumatoid arthritis, DXL702 for the treatment of breast cancer and DXL1215 targeting endometriosis.

Company: Inovio Biomedical Corporation Ticker Symbol & Exchange: INO - AMEX Investor Relations Contact: Bernie Hertel

Investor Relations Contact Phone: 858 410 3101 Web: www.inovio.com Date of Presentation: 11/10/2008

Inovio Biomedical is focused on developing DNA vaccines for cancers and infectious diseases using its novel method for DNA delivery electroporation - which uses brief, controlled electrical pulses to increase cellular uptake of useful biopharmaceuticals. Initial human data has shown that Inovio's electroporation delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, Tripep, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio is also conducting proprietary vaccine R&D. The company's technology is protected by an extensive patent portfolio covering in vivo electroporation.

Company: InterAmerican Acquisition Group Inc. Ticker Symbol & Exchange: IAQG.OB, OTCBB

Investor Relations Contact: Mr. Crocker Coulson Investor Relations Contact Phone: 646-213-1915 Web: www.cncdev.com Date of Presentation: Wednesday, November 12, 2008

InterAmerican Acquisition Group Inc. raised $46 million in a Sept.

2007 IPO and recently announced plans to acquire Sing Kung, Ltd. The combined company, China New Cities Development Ltd. ("CNC") will continue to deliver comprehensive planning and infrastructure build-outs to selected municipalities throughout China. CNC's "Build-Transfer" business model allows local governments to overcome financial and project management constraints and to quickly unlock economic development potential and property value. CNC employs unique capabilities and exceptional strategic relationships to deliver turnkey solutions to progressive cities that are expanding or redeveloping urban cores to meet explosive growth. CNC is profitable (34% pre-tax 1st half) and growing rapidly, driven by strong macroeconomic and demographic factors in China.

Company:

Interleukin Genetics, Inc. Ticker Symbol & Exchange: AMEX: ILI Investor Relations Contact: Melanie Friedman Investor Relations Contact Phone: 212-362-1200 Web: http://www.ilgenetics.com Date of Presentation: 11/10/2008

Interleukin Genetics is a leading, genetics-focused personalized health company developing preventive consumer products and genetic tests for the emerging personalized health market. Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin has commercialized several genetic tests: the PSTÂŽ Periodontal genetic test, the GensonaÂŽ IL-1 Cardiovascular genetic test and the GensonaÂŽ General Nutrition genetic test. Interleukin is developing additional genetic tests to address significant health risks for osteoporosis, obesity, arthritis and cancer. Interleukin also offers an array of Nutraceuticals which are sold at the nation's largest food, drug and mass retailers.

Company: International Montoro Resources Ticker Symbol & Exchange: TSX-V: IMT Investor Relations Contact: Christopher Haldane Investor Relations Contact Phone: 416.868.1079 ex.237 Web: www.montororesources.com Date of Presentation: 11/11/2008

International Montoro Resources is charging forward in the cleaner energy world of tomorrow. Montoro is currently advancing uranium projects in the world's powerhouse region for Uranium - Saskatchewan (Crackingstone/Orbit-Uranium City) and Ontario (Elliot Lake)-once known as the Uranium Capital of the World. While many uranium companies are spending their investment dollars in one province or region, Montoro and its joint venture partners are currently advancing two projects in two separate regions, managing the risk for their investors to maximize potential in becoming a "True North" cleaner and greener uranium mining company.

Company: Iteris, Inc. Ticker Symbol & Exchange: ITI (AMEX) Investor Relations Contact: Brett Maas Investor Relations Contact Phone: 646-536-7331 Web: www.iteris.com Date of Presentation: 11/10/2008

Iteris, Inc. is a leader in the traffic management market focused on the development and application of advanced technologies that reduce traffic congestion, minimize the environmental impact of traffic congestion and improve the safety of surface transportation systems.

Combining outdoor image processing, traffic engineering and information technology, Iteris offers a broad range of Intelligent Transportation Systems and driver safety solutions to customers worldwide. Iteris is headquartered in Santa Ana, California with offices throughout the U.S., Europe, and Asia. Investors are encouraged to contact us at 888-329-4483, or at www.iteris.com.

Company: Javelin Pharmaceuticals, Inc. Ticker Symbol & Exchange: AMEX: JAV Investor Relations Contact: Rick Pierce Investor Relations Contact Phone: 617-499-4703 Web: www.javelinpharma.com Date of Presentation: 11/10/2008

Javelin Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets innovative proprietary products to treat acute moderate-to-severe pain in medically supervised settings. The company's product candidates offer faster relief of pain, with potentially fewer adverse side effects compared to other currently available treatments. Javelin seeks to reduce development risk and maximize commercial opportunity through novel administration routes, novel formulations and new labeling for existing FDA approved active pharmaceutical ingredients. The company's product candidates also enjoy robust global patent protection.

Company:

Jennerex, Inc. Investor Relations Contact: Ian Malone Investor Relations Contact Phone: 613-730-8019 Web: www.jennerex.com Date of Presentation: 11/11/2008

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position.

Company: Jingwei International Limited Ticker Symbol & Exchange: JNGW Investor Relations Contact: Regis Kwong Investor Relations Contact Phone: 86-10-85885690 Web: www.jingweicom.com Date of Presentation: November 10th

Jingwei International Limited has evolved into an integrated marketing services provider, powered by its consumer database and data mining capabilities. The Company is known as one of the leaders in providing direct marketing services to global companies doing business in China. Jingwei's proprietary data base of over 300M Chinese consumers as well as its real time analysis tools, enable its customers to create and manage their advertising content and monitor results, while improving immediately ROI. In addition, the Company has a geographic presence in 20 cities throughout China and an executive and technical team that has global experience in the direct marketing space. As multinational and domestic companies in China increase their penetration of the rapidly expanding Chinese market they seek to reach the appropriate

targeted audience

Company: Kinbauri Gold Corp.

Ticker Symbol & Exchange: KNB (TSXV) Investor Relations Contact Phone: Darrell Munro 613-836-0198 Web: www.kinbauri-gold.com Date of Presentation: November 11 Kinbauri is a TSX Mineral Exploration Company focused on the development of mineral properties, primarily precious metal prospects in northwestern Spain. Its immediate focus is to expand and upgrade resources to reserves at the El Valle property in Asturias, Spain in order to start operations at the mine and existing mill complex there in 2010.

Kinbauri To Become Western Europe's Largest Gold Producer Current Resources stand at 2.2M ounces of gold and 157 Million Pounds of Copper. Kinbauri has over $100M of infrastructure on site including a fully operational Mill and is targeting production of 145,000 ounces of gold equivalent per year.

Company: Kodiak Exploration Limited Ticker Symbol & Exchange: TSXV:KXL Investor Relations Contact: Brian Maher, Bill Chornobay Investor Relations Contact Phone: 1-888-688-9006 Web: www.kodiakexp.com Date of Presentation: Tuesday November 11, 2008

Kodiak Exploration Limited is an excellent exploration company with a new high-grade gold discovery in the Beardmore-Geraldton gold camp in Ontario, Canada. The Golden Mile was recently recognized by industry peers as Discovery of the Year. Kodiak controls the majority of this underexplored gold camp, and is simultaneously exploring numerous other stand-alone targets. With excellent infrastructure, experienced management, $40 million cash, and no debt, Kodiak enjoys very strong institutional support, and is on track to achieve its short and long term objectives. On October 30, Kodiak was rated Outperform at $4 by National Bank Financial.

Company: Labrador Iron Mines Holdings Limited Ticker Symbol & Exchange: TSX:LIR Investor Relations Contact: John F. Kearney Investor Relations Contact Phone: John F. Kearney, (647)728-4125 Web: www.labradorironmines.ca Date of Presentation: 11/10/2008

Labrador Iron Mines Holdings Limited is developing "direct shipping" iron ore deposits in the Labrador Trough, in the province of Newfoundland and Labrador, near Schefferville, Quebec, Canada.

The Company was listed on the TSX in December 2007, following a successful IPO in which it raised over $52 million.

Over 150 million tons of direct shipping iron ore was previously mined by the Iron Ore Company from 1954 to 1982.

LIM's operations will utilize much of the existing infrastructure constructed for the former operations. Mining will be open pit

methods and broken ore will be screened and washed to upgrade iron content prior to rail shipment.

Labrador Iron Mines is targeting to commence production of both lump and sinter fine ore in 2009.

Company: Laurion Mineral Exploration Inc. Ticker Symbol & Exchange: TSXV: LME Investor Relations Contact: CHF Investor Relations Investor Relations Contact Phone: Jacqueline Wagenaar, (416) 868-1079 x289 Web: www.laurion.ca Date of Presentation: November 11th, 2008 at 11:10am

Laurion Mineral Exploration Inc. is an exploration stage company engaged in the acquisition, exploration and development of its highly prospective base metals, platinum group elements (PGEs) and gold properties in Northern Ontario. In addition, Laurion is aggressively pursuing the acquisition of advanced exploration properties that are near to production either locally or

internationally.

Laurion's flagship property the Sturgeon River Project, which has received numerous market interest, is a past producing gold project located in the Geraldton-Beardmore Gold Camp which has reportedly produced more than 4.12M ounces since 1925.

Company: Lectus Therapeutics Limited Investor Relations Contact: Roland Kozlowski, CEO Investor Relations Contact Phone: 44 (0)1223 499050 Web: www.lectustherapeutics.com Date of Presentation: November 12th

Lectus Therapeutics Limited is a Cambridge (UK)-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics for pain management and related indications.

Lectus exploits the power of its proprietary functional proteomics platform, LEPTICSÂŽ, and builds on its

knowledge of ion channels and protein-protein interactions, to identify and develop next-generation channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Lectus has attracted a top tier syndicate of investors (including Sofinnova Partners, Spark Ventures, Takeda Research Investment and Astellas Venture Management) to support advancement of the company's existing discovery programmes.

Company: LightPath Technologies, Inc. Ticker Symbol & Exchange: NASDAQ: LPTH Investor Relations Contact: Mark McPartland Investor Relations Contact Phone: (910) 221-1827 Web: www.lightpath.com Date of Presentation: Monday, November 10th at 3:40 p.m.

LightPath manufactures optical products including precision molded aspheric optics, GRADIUMÂŽ glass products, proprietary collimator assemblies, laser components

utilizing proprietary automation technology, higher-level assemblies and packing solutions. LightPath has a strong patent portfolio that has been granted or licensed to us in these fields. LightPath common stock trades on The Nasdaq Capital Market under the stock symbol LPTH. For more information visit www.lightpath.com

Company: Medgenics Ticker Symbol & Exchange: (AIM: MEDG) Investor Relations Contact: Leslie Wolf-Creutzfeldt Investor Relations Contact Phone: (646) 284-9472 Web: http://www.medgenics.com Date of Presentation: 11/12/2008

Medgenics, Inc. is a clinical-stage biopharmaceutical company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases.

Medgenics currently has two products in development based on this

technology: EPODURE - producing erythropoietin (EPO) to treat anaemia INFRADURE - producing interferon-alpha (IFN-alpha) to treat hepatitis C

The Company has demonstrated proof of principle of the Biopump treatment procedure in a clinical trial using a short-acting version of EPODURE in anemic subjects. The Company commenced a Phase I/II clinical trial for its long-acting version of EPODURE, designed to produce and deliver a therapeutic dose of EPO steadily for three to six months or more, in August 2008.

Company: Medivir AB Ticker Symbol & Exchange: OME: MVIRB SS Investor Relations Contact: Mr Rein Piir Investor Relations Contact Phone: 46 708 53 72 92 Web: www.medivir.com Date of Presentation: 11/12/2008

Medivir develops pharmaceuticals and has several collaborations with established pharmaceutical companies as well as smaller biotech enterprises.

The majority of our projects are based on developing protease inhibitors into innovative drugs and we have a strong commitment in the development of hepatitis C pharmaceuticals.

In clinical development phase there is one investigational drug against labial herpes were Medivir recently filed an NDA in both USA and Europe. Two projects target HCV; TMC435350 in clinical phase II and the other in preclinical development phase. Furthermore there are three projects in phase II and two in phase I and several protease projects in late preclinical stage.

Company: Midnight Oil Exploration Ltd. Ticker Symbol & Exchange: MOX: TSX Investor Relations Contact: Jo Ellen Krchnak Investor Relations Contact Phone: 403-303-8510 Web:

www.midnightoil.ca Date of Presentation: 11/10/2008

Midnight is a top quality junior exploration and production company that focuses on the selected multi-zone, high potential areas of the Western Canadian Sedimentary Basin. Midnight employs a proven formula combining a high-end technical team with experience, expertise, and innovative operational and business execution skills to provide a competitive edge in our areas of operation. Midnight is an active practitioner of the latest technical advances in geology, geophysics, reservoir engineering, drilling and completions and has recently acquired a large holding on a tight gas resource play within the sweet spot of the Deep Basin at Elmworth and Wapiti.

Company: MiMedx Group, Inc. Ticker Symbol & Exchange: OTCBB: MDXG Investor Relations Contact: John Thomas Investor Relations Contact Phone: 770-514-0077 Web: www.mimedx.com

Date of Presentation: 11/10/2008

MiMedx Group, Inc., (MDXG) is an integrated developer, manufacturer, and marketer of patent protected, spine and orthopedic implants which represent breakthroughs in the treatment of trauma and disease. The company is positioned for rapid growth in revenues and profits.

Utilizing novel materials and techniques, our products are implants intended to competitively address a broad range of acute and chronic musculoskeletal diseases and disorders in the spine, orthopedic, and general surgery marketplace.

The markets for the specific indications our products address is estimated at over $7.5 billion* and projected to grow at a compound annual rate of > 20% a year through 2025.

Company: Molecular Insight Pharmaceuticals, Inc. Ticker Symbol & Exchange: NASDAQ: MIPI Investor Relations Contact: Deborah S. Lorenz

Investor Relations Contact Phone: 617-492-5554 Web: www.molecularinsight.com Date of Presentation: 11/12/2008

Molecular Insight Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The Company is focused on discovering, developing and commercializing innovative molecular imaging radiopharmaceuticals and targeted molecular radiotherapeutics with initial applications in the areas of cardiology and oncology.

Company: Momenta Pharmaceuticals, Inc. Ticker Symbol & Exchange: MNTA - NASDAQ Investor Relations Contact: Beverly Holley Investor Relations Contact Phone: 617-395-5189 Web:

www.momentapharma.com Date of Presentation: November 11th, 12:25pm

Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of technology-enabled generic drugs, re-engineered drugs and novel drug candidates.

Company: MorphoSys AG Ticker Symbol & Exchange: FSE (Germany): MOR Investor Relations Contact: Ms. Claudia Gutjahr Investor Relations Contact Phone: +49 (89) 899 27-404 Web: www.morphosys.com Date of Presentation: Nov. 11th, 2008

MorphoSys AG, located in Martinsried/Munich (Germany), is one of the

world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies, such as Merck&Co, Novartis, Pfizer, and Roche.

The Company possesses the unique HuCAL technology (the Human Combinatorial Antibody Library). This library comprises more than ten billion different, fully human antibodies. HuCAL is a very powerful technology, which allows rapid and automated production of high-affinity antibodies.

Company: Morria Biopharmaceuticals Plc Investor Relations Contact: Yuval Cohen Investor Relations Contact Phone: 917-361-5210 Web: www.morria.com Date of Presentation: Nov 10: from 10:45 to 11:10 AM

Morria Biopharmaceuticals Plc (founded 2005) is focused on the

development of novel, non-steroidal anti-inflammatory drugs. Lead products are first-in-class, synthetic drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These unique drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage. Morria has two lead products in clinical development MRX-4 (allergic rhinitis, Phase II) and MRX-6 (contact dermatitis, Phase II) and a growing library of additional compounds targeting IBD, ophthalmology and cystic fibrosis. To-date, this private company has raised $7m and is preparing for a round C of $10m-$15m.

Company: Neotropix Inc. Investor Relations Contact: LaVoie Group Investor Relations Contact Phone: Lisa Rivero, 617-947-0899 Web: Neotropix.com Date of Presentation: November 10, 2008 4:55 PM Louis Roo

Neotropix began operations in 2005 to develop and commercialize naturally derived, systemically deliverable oncolytic viruses for

the treatment of solid tumors. The company has brought three of the candidates into pre-clinical testing one of which (NTX-010) is in a large US phase I/II study being conducted at 11 sites testing the drug over a range of neuroendocrine cancers at various doses. The Phase I/II trial is expected to complete enrollment in Q4 2008 with full data disclosure in 2009. Additionally, the company is planning a phase II/III trial in Small Cell Lung Cancer based upon the results observed in the Phase I/II

Company: NetSol Technologies Ticker Symbol & Exchange: (NASDAQ:NTWK) Investor Relations Contact: Christopher Chu Investor Relations Contact Phone: 646-284-9426 Web: www.netsoltech.com Date of Presentation: 11/10/2008

NetSol Technologies is a U.S. corporation providing global business services and enterprise application solutions to private and public sector organizations worldwide. NetSol uses its BestShoring(TM)

practices and highly experienced resources in analysis, development, quality assurance, and implementation to deliver high-quality, cost-effective solutions. Organized into specialized industries, these product and services offerings include portfolio management systems for the financial services industry, consulting, custom development, systems integration, and technical services for the global healthcare, insurance, real estate, and technology markets.

Company: Neuralstem, Inc. Ticker Symbol & Exchange: Amex: CUR Investor Relations Contact: Steve Chizzik Investor Relations Contact Phone: 908-688-9111 Web: www.neuralstem.com Date of Presentation: Monday, November 10, 2008

Neuralstem targets Major Central Nervous System diseases with its patented stem cell technology. Research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS

(Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE in June 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the near future.

Company: Nevsun Resources Ticker Symbol & Exchange: NSU on TSX and AMEX Investor Relations Contact: John Clarke Investor Relations Contact Phone: 604 623 4700 Web: nevsun.com Date of Presentation: 11/12/2008

Nevsun Resources Ltd. is a TSX/AMEX listed junior focused on developing gold & base metals projects in Africa.

Nevsun's Bisha Mine in Eritrea will be a

low cost gold producer for its first two years of production (approx. 430,000 ounces gold per year) and a low cost high grade copper concentrate producer (containing approx. 75,500 tonnes of contained copper metal per year) for a further three years.

Thereafter the mine will produce separate zinc and copper concentrates.

Company: NGAS Resources, Inc. Ticker Symbol & Exchange: NGAS Investor Relations Contact: Kathleen Heaney Investor Relations Contact Phone: 203-803-3585 Web: www.ngas.com Date of Presentation: Wed., Nov. 12, 2008, 11:10 a.m. (E)

NGAS (Nasdaq: NGAS) is an Exploration & Production company focused on unconventional natural gas plays in the eastern U.S., primarily in the southern portions of the Appalachian and Illinois Basins.

The company has specialized in generating and developing geological prospects for over 20 years.

NGAS holds 366,000 acres of oil and gas leases for development, owns interests in over 1,300 wells, and 636 miles of gas gathering pipeline. Ninety percent of the company's southern Appalachian gas production is delivered directly from the wellhead to the interstate gas transportation system.

Company: Novelos Therapeutics, Inc. Ticker Symbol & Exchange: OTCBB: NVLT Investor Relations Contact: Stephen Lichaw Investor Relations Contact Phone: 201-240-3200 Web: www.novelos.com Date of Presentation: November 10, 2008, 10:45am

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a

chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer.

NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed.

Company: NPS Pharmaceuticals Ticker Symbol & Exchange: NPSP - NASDAQ Investor Relations Contact: Susan Mesco Investor Relations Contact Phone: 908-450-5516 Web: www.npsp.com Date of Presentation: 11/11/2008

NPS Pharmaceuticals is a New Jersey based biopharmaeutical company focused on the development and commercialization of specialty therpaeutics for gastrointestinal and endocrine disorders with high unmet medical needs. The company is currently advancing two

late-stage programs. Teduglutide, a proprietary analog of GLP-2, is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome as GATTEX and in preclinical development for gastrointestinal mucositis and pediatric gastrointestinal conditions. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as hormone therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes partnerships with Amgen, GSK, Kirin and Nycomed.

Company: Nuinsco Resources Limited.

Ticker Symbol & Exchange: Toronto, symbol NWI Investor Relations Contact: Sean Stokes Investor Relations Contact Phone: 416-626-0470 Web: www.nuinsco.ca Date of Presentation: Nov. 12

Nuinsco is a growth-oriented, multi-commodity mineral exploration

and development company that is prepared for production and focused on growth through nickel, copper, zinc, uranium and gold exploration and development in world-class mineralized belts in Canada and Turkey. Shares of Nuinsco trade on the Toronto Stock Exchange under the symbol NWI.

Company: OMNI Energy Services Corp Ticker Symbol & Exchange: OMNI NASDAQ Investor Relations Contact: Ron Mogel, Sr. Vice President & Chief Financial Officer Investor Relations Contact Phone: 337/896-6664 Web: omnienergy.com Date of Presentation: November 11, 2008, 10:20 a.m. - Spellman Salon (5th Floor)

Formed in 1987, OMNI Energy Services Corp. has evolved into a premier service provider to the oil and gas industry. Through our integrated services group of companies we focus on three core business units: Seismic Services, Land Operations, and Offshore Operations. Our activities are concentrated in the most prolific regions in the U.S.; on land, inland and offshore. OMNI Seismic

Drilling is the unmatched provider of choice among companies engaged in acquisition of 3D seismic data in regions we serve. From exploration through drilling and production, OMNI has the scale and scope to be our customers' single-source provider of choice.

Company: Oncolytics Biotech Inc. Ticker Symbol & Exchange: TSX:ONC, NASDAQ:ONCY Investor Relations Contact: Cathy Ward Investor Relations Contact Phone: 403.670.7370, cathy.ward@oncolytics.ca Web: www.oncolyticsbiotech.com Date of Presentation: Nov. 11

Oncolytics Biotech Inc. is conducting a broad clinical trial program in the U.S. and the U.K. with the objective of developing REOLYSINÂŽ as a human cancer therapeutic. The current clinical program includes 12 Phase I/II or Phase II human trials examining REOLYSINÂŽ alone or in combination with radiation, chemotherapy, or immune modulation.

This broad clinical program is designed to identify targets for late-stage registration trials with REOLYSINÂŽ.

The current program is treating patients with a wide variety of advanced cancers including head & neck, sarcoma, non-small cell lung, melanoma and ovarian.

Company: OncoVista Innovative Therapies, Inc. Ticker Symbol & Exchange: OVIT.OB Investor Relations Contact: Aimee Boutcher Investor Relations Contact Phone: (973) 239-2878 Web: http://www.oncovista.com Date of Presentation: 11/11/2008

We are a biopharmaceutical company that is commercializing diagnostic tests for metastatic tumors as well as developing targeted anticancer therapies by utilizing tumor-associated biomarkers. Our metastatic breast and colon cancer kits are marketed in Europe and a CLIA lab is established in US. Biomarker use should

increase clinical response rates, thereby expediting drug development and reducing costs. Our targeted drugs are:

oOVI 123 - Phase I/II leukemia trial underway in US at two sites oOVI 237 - Phase II metastatic breast cancer trial planned for Europe oOVI-117 - IND in preparation for solid tumor clinical trial

Company: Oramed Pharmaceuticals Ticker Symbol & Exchange: OTC BB:ORMP Investor Relations Contact: Eric Rosenberg Investor Relations Contact Phone: 972 545 667713 Web: www.oramed.com Date of Presentation: Nov 11: from 04:05 to 04:30 PM

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via

injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

Company: Osteologix, Inc. Ticker Symbol & Exchange: OTCBB: OLGX Investor Relations Contact: Baxter Phillips, III Investor Relations Contact Phone: 804-747-6026 Web: www.osteologix.com Date of Presentation: Monday, November 10, 2008

Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. It is our vision to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis.

We partner with the healthcare community to apply new scientific information and clinical data to the development of products that improve patient care in a safe and ethical manner. Osteologix's lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis.

Company: Oxygen Biotherapeutics, Inc. Ticker Symbol & Exchange: OXBO:OTCBB Investor Relations Contact: Abe Wischnia Investor Relations Contact Phone: 619-795-2345 Web: www.oxybiomed.com Date of Presentation: Nov. 12, 2008

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (OxycyteÂŽ) and an implantable glucose sensor. These products are based upon

core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.

Company: PAION AG Ticker Symbol & Exchange: PA8 (FSE), PAI (AIM) Investor Relations Contact: Dr. Peer Nils Schroeder Investor Relations Contact Phone: 49 241 4453-152 Web: www.paion.com Date of Presentation: 11/10/2008

PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals in June 2008, the company has a second site in Cambridge, UK. The company is specializing in developing and commercializing innovative drugs for

the hospital-based treatment of CNS disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need. PAION intends to further expand its portfolio of drugs by exploiting its core expertise in identifying high-potential compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. Where appropriate, PAION seeks to collaborate with experienced partners.

Company: PanTerra Resource Corp Ticker Symbol & Exchange: 'PAN' - TSX-V Investor Relations Contact: Fred Rumak Investor Relations Contact Phone: Herve Collet, 403-261-5900 Web: www.panterraresource.com Date of Presentation: 11/12/2008

PanTerra Company Overview:

-3 years from idea to reality

-Large land base, 1.1 million acres (550,000 net) acquired in 2005 and earned in 2006.

-Drilled and cased 39 wells to date.

-Extensive coring and geochemical sampling.

-Developing resource play to "proven reserve" stage.

-Widely held stock base with one major shareholder at 15%

-Proving reserve base with leading edge technology out of the USA.

-Management has over 67 years experience in engineering and geology with both domestic and international experience and 40 plus years of financial experience.

-Objective is to prove reserve base and develop same and or dispose of same to larger entity.

-Strategically located geographic location of land.

Company: Parallel Petroleum Corporation Ticker Symbol & Exchange: NASDAQ: PLLL Investor Relations Contact: Cindy Thomason, Mgr Inv Rel

Investor Relations Contact Phone: 432-684-3727 Web: www.plll.com Date of Presentation: Tuesday, November 11, 2008

Parallel Petroleum is an independent energy company headquartered in Midland, Texas, engaged in the exploitation, development, acquisition, and production of oil and gas using 3-D seismic technology and advanced drilling, completion and recovery techniques, including horizontal drilling and fracture stimulation.

Parallel's primary areas of operation are the Permian Basin of West Texas and New Mexico, North Texas Barnett Shale, Onshore Gulf Coast of South Texas, East Texas and Utah/Colorado.

Company: Pelangio Exploration Inc. Ticker Symbol & Exchange: PX Investor Relations Contact: Brendan Cahill Investor Relations Contact Phone: 905-875-3828

Web: www.pelanigo.com Date of Presentation: November 11, 2008 at 4:05 - 4:30 PM

Pelangio is a Canadian junior mineral exploration company, with a focus on gold, active in two of the top-ranked mining jurisdictions in the world, Canada and Ghana. The Company focuses on the acquisition and exploration of under-valued or early stage exploration prospects located in world-class gold belts, where discovery can provide a significant return on investment.

Company: Peplin Ticker Symbol & Exchange: ASX: PLI Investor Relations Contact: Tom Wiggans Investor Relations Contact Phone: 510-653-9702 Web: www.peplin.com Date of Presentation: November 11, 2008

Peplin is a development stage pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. We are currently developing our patented PEP005 (ingenol mebutate), first in a new class of compounds that is extracted and purified from Euphorbia peplus, a readily-available plant.

Our lead product candidate, currently in PIII trials (REGION-I) under an SPA, is a patient-applied gel containing PEP005 for the treatment of actinic keratosis (AK). AK is generally considered the most common pre-cancerous skin condition, where lesions may progress to squamous cell carcinoma.

After completing a $24m financing, Peplin has $56m, sufficient to complete Phase III development.

Company: PhotoMedex, Inc. Ticker Symbol & Exchange: NasdaqGM: PHMD Investor Relations Contact: Kim Golodetz Investor Relations Contact Phone: (212) 838-3777 Web: KGolodetz@lhai.com

Date of Presentation: 11/11/2008

PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care.

PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company.

ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Company: Polaris Minerals Corporation Ticker Symbol & Exchange: PLS:TSX Investor Relations Contact: Mike Westerlund Investor Relations Contact Phone: 604.915.5000 ext 104

Web: www.polarmin.com Date of Presentation: 11/11/2008

Polaris Minerals Corporation is exclusively focused on the development of quarries and the production of construction aggregates on Vancouver Island, British Columbia, for marine transport by bulk carriers to urban markets on the west coast of North America to meet growing local supply deficits.

In 2007, Polaris began shipping sand and gravel from the Orca Quarry to readymix concrete companies in San Francisco, Vancouver and Hawaii. Polaris has long-term supply contracts with its customers and stable, long-term shipping contracts.

Polaris owns 88 percent of the Orca Quarry and 70 percent of the proposed Eagle Rock Quarry.

Company: Prana Biotechnology Ltd Ticker Symbol & Exchange: NASDAQ:PRAN/ASX:PBT Investor Relations Contact: Leslie Wolf-Creutzfeldt

Investor Relations Contact Phone: 646-284-9472 Web: www.pranabio.com Date of Presentation: Nov 10, 9:55am

Prana Biotechnology Limited ("Prana") was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Its mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration for the brain as the aging process progresses.

Researchers at prominent international institutions including the University of Melbourne, the Mental Health Research Institute (Melbourne), and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana's technology. Prana is now regarded as one of the leading contenders in the field of neuro-degenerative disease. Prana has completed Phase IIa trial with its leading compound PBT2 and has obtained positive results.

Company: Provectus Pharmaceuticals, Inc.

Ticker Symbol & Exchange: PVCT:BB Investor Relations Contact: Peter R. Culpepper Investor Relations Contact Phone: 866-594-5999 #30 Web: www.pvct.com Date of Presentation: November 11th, 2008

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology.

Company: Puda Coal, Inc.

Ticker Symbol & Exchange: PUDC Investor Relations Contact: Ms Laby Wu Investor Relations Contact Phone: 86-139-1129-6720 Web: www.pudacoalinc.com Date of Presentation: 11:35 am - 12:00 pm on Nov. 11th 08

Puda Coal, through its subsidiaries, supplies premium grade coking coal to the steel making industry in China for use in making coke.

The company currently possesses 3.5 million metric tons of annual coking coal cleaning capacity. Shanxi Province provides 20 - 25% of China's coal output and supplies nearly 50% of China's coke. For more information, visit www.pudacoalinc.com.

Company: QRxPharma Ticker Symbol & Exchange: ASX:QRX -OTCQX:QRXP Investor Relations Contact: John Holaday Investor Relations Contact Phone:

john.holaday@qrxpharma.com, 908-506-2900 Web: www.qrxpharma.com Date of Presentation: November 10, 2008, 12:25 pm, Holmes

QRxPharma is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders.

Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales.

The worldwide market for the treatment of moderate to severe pain with opioids exceeds $10BB, and in the US, $7BB annually. QRxPharma intends to directly commercialize its products in the US and seek strategic partnerships abroad.

Company: Raptor Pharmaceuticals Corp.

Ticker Symbol & Exchange: RPTP.OB Investor Relations Contact: Sara Ephraim, The Ruth Group Investor Relations Contact Phone:

646.536.7002 Web: www.raptorpharma.com Date of Presentation: Nov. 11, 9:30-9:55 am, Holmes II

Raptor Pharmaceuticals Corp. (OTCBB: RPTP) is dedicated to speeding the delivery of new treatment options by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor is developing its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease and Batten Disease, and its Convivia product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical program Raptor bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins which are designed to target cancer, neurodegenerative disorders and infectious diseases.

Company: Reed Resources Ltd Ticker Symbol & Exchange: RDR:ASX Investor Relations Contact:

Simon Hicks Investor Relations Contact Phone: 61-8-9322 1182 Web: www.reedresources.com Date of Presentation: 11/11/2008

Reed Resources Ltd intends on being one of the world's lowest cost producers of ferrovanadium. It is currently carrying out a Definitive Feasibility Study into the production of 6300t p.a. of ferrovanadium from it's Barrambie Vanadium Project.

Reed Resources is also a gold miner and an active explorer for gold and base metals in Western Australia.

The company is listed on the Australian Securities Exchange (ASX Code: RDR).

Company: Repros Therapeutics Inc. Ticker Symbol & Exchange: RPRX Investor Relations Contact: Joe Podolski

Investor Relations Contact Phone: 281-719-3447 Web: www.reprosrx.com Date of Presentation: 11/11/2008

Repros Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of new, orally administered, small molecule drugs to treat hormonal and reproductive system disorders. The company has two lead product candidates.

ProellexÂŽ, for the treatment of adverse symptoms associated with uterine fibroids, has shown statistically significant improvement in the primary endpoints in Phase 2 trials.

Also ProellexÂŽ has demonstrated superior efficacy and safety in endometriosis when compared to the standard of drug care and is currently in Phase 2.

Androxal(TM), for the treatment of testosterone deficiency, has shown highly statistically significant positive effects in men with secondary hypogonadism and is in Phase 2.

Company:

Rex Energy Corporation Ticker Symbol & Exchange: REXX Investor Relations Contact: Joseph DeSimone Investor Relations Contact Phone: 814-278-7129 Web: www.rexenergy.com Date of Presentation: November 11, 2008 @ 4:30 p.m.

Rex Energy Corporation is an independent oil and gas company operating in the Illinois Basin, the Appalachian Basin and the Southwestern Region of the United States. The company has pursued a balanced growth strategy of exploiting its sizable inventory of lower risk developmental drilling locations, pursuing its higher potential exploration drilling prospects and actively seeking to acquire complementary oil and natural gas properties.

Company: Rib-X Pharmaceuticals, Inc. Investor Relations Contact: John Capodanno Investor Relations Contact Phone:

212-850-5705 Web: www.rib-x.com Date of Presentation: 11/10/2008

Rib-X Pharmaceuticals, Inc. is designing and developing novel antibiotics. Rib-X's underlying drug discovery engine combines its proprietary high-resolution X-ray crystal structure of the 50S ribosome and computational tools to rapidly synthesize new antibiotics that avoid known resistance mechanisms and have a superior spectrum. Rib-X has four programs; radezolid an oral/IV oxazolidinone for treating serious Gram-positive infections and delafloxacin, a fluoroquinolone active against quinolone-resistant Gram-positive bacteria and MRSA, both having completed Phase 2 clinical studies; and two pre-clinical programs, Rx-04 a novel class of antibiotics active against multi-drug resistant Gram-negative bacteria and Rx-02 an IV/oral macrolide for MRSA and multidrug-resistant Streptococcus.

Company: Richmont Mines, Inc. Ticker Symbol & Exchange: TSX-NYSEAlternext Investor Relations Contact:

James M. Culligan Investor Relations Contact Phone: 716-843-3874 Web: www.richmont-mines.com Date of Presentation: 11/10/2008

Richmont Mines produces gold from its operations in Canada and is focused on building its reserves in North America. The Company has extensive experience in gold exploration, development and mining.

Since it began production in 1991, the Company has produced more than one million ounces of gold from its holdings in Quebec, Ontario and Newfoundland.and Labrador. Richmont Mines' strategy is to cost effectively develop its mining assets, exploit mineralized reserves on properties owned and acquired, or develop partnerships to expand its reserve base.

Company: RINO International Corp.

Ticker Symbol & Exchange: RINO OTCBB Investor Relations Contact: HC International, Inc. Investor Relations Contact Phone:

Ted Haberfield, 760-755-2716 Web: www.rinogroup.com Date of Presentation: 11/12/2008

Rino develops, produces and installs pollution control and Cleantech equipment for customers operating in China's Iron and Steel sector. RINO has three specific areas its products address which include water, air and production efficiency. As the government continues to implement more stringent emission and pollution standards, the Company's products have seen a significant increase in demand, as its customized desulphurization equipment have been a primary driver during the previous 12 months.

Company: Rockwell Medical Technologies, Inc. Ticker Symbol & Exchange: NASDAQ: RMTI Investor Relations Contact: Brian Korb Investor Relations Contact Phone: 646-378-2923 Web:

http://www.rockwellmed.com/ Date of Presentation: 11/12/2008

Rockwell Medical is a leading, innovative manufacturer and developer of renal drug therapies and dialysis products. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. SFP, the Company's lead renal drug, is a water-soluble iron designed to provide physiological-iron-maintenance-therapy for the treatment of anemia, with initial indication for end stage renal disease (ESRD). There are an estimated 370,000 ESRD patients in the United States growing approximately 3-5% on average each year and approximately 2 million ESRD patients world-wide. SFP is currently in Phase II-b and NIH-funded studies, with data expected next year.

Company: Santaris Pharma A/S Investor Relations Contact: Randi Krogsgaard Investor Relations Contact Phone: 45 45179879 Web: www.santaris.com Date of Presentation:

11.11.08

Santaris Pharma is a Danish clinical stage biopharmaceutical company formed in 2003. The Company has exclusive pharmaceutical rights to LNA technology used to develop new classes of RNA medicines to silence mRNAs and microRNAs associated with cancer, metabolic disorders and viral infections. In 2006 the Company completed a Euro 40m second round and in 2007 a Euro 20m third round of equity financing. Santaris Pharma has a global alliance with Enzon Pharmaceuticals to develop and co-commercialise cancer drugs and a worldwide strategic alliance with GlaxoSmithKline for the discovery, development and commercialization of antiviral medicines. In May 2008 the Company initiated the world's first human trial with a microRNA drug candidate, SPC3649, targeting microRNA-122, which is associated with HCVreplication in the liver.

Company: SciClone Pharmaceuticals Ticker Symbol & Exchange: NASDAQ: SCLN Investor Relations Contact: Ana Kapor Investor Relations Contact Phone: 650 350 4825 Web:

www.sciclone.com Date of Presentation: Wednesday, November 12 2008

SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. SciClone's strategy is to develop late-stage clinical products for commercialization in the United States, Europe, and China, one of the world's fastest growing pharmaceutical markets.

Company: Shiner International, Inc. Ticker Symbol & Exchange: BEST (NASDAQ) Investor Relations Contact: Mr. Arnold Staloff Investor Relations Contact Phone: 212-631-3510 Web: www.shinerinc.com Date of Presentation: 11/12/2008 15:15

Shiner International, Inc. is a highly profitable U.S. public company with its main business in China.

Shiner is China's leading manufacturer and marketer of four types of technology driven packaging film products: anti-counterfeit films, coated films, BOPP films and color printed films. Serving customers worldwide, Shiner is one of the few large scale global suppliers dedicated to the manufacturing of advanced packaging films. Our products are used to seal in freshness and flavor, protect goods from product tampering, and extend foods and beverages shelf life.

Shiner holds 13 patents on products and production equipment with additional patents pending.

Company: Silver Shield Resources Corp.

Ticker Symbol & Exchange: SSR: TSX.V Investor Relations Contact: Lindsay Carpenter Investor Relations Contact Phone: lindsay@chfir.com, 416-868-1079 ext. 239 Web: www.silvershieldresources.com Date of Presentation: 11/10/2008

Silver Shield Resources is a mineral exploration company established to discover and develop mineral resources, with a focus on silver and an interest in gold. Silver Shield's corporate objective is to acquire quality silver projects which are in advanced stages, beyond grassroots exploration and have the potential to be developed into producing properties. The company's properties are located in historical producing belts in Mexico and Northern Ontario, and are shallow deposits resulting in low cost exploration and development. The company's two flagship properties are 100% owned, with high grade assay results at mineable widths from a first phase of drilling on both these properties, La Cumbre (Mexico) and Welsh Silver Mine (Northern Ontario).

Company: Skygold Ventures Ltd. Ticker Symbol & Exchange: TSX-V : SKV Investor Relations Contact: Brad Aelicks Investor Relations Contact Phone: 604.685.6465 Web: www.skygold.ca

Date of Presentation: 11/12/2008

Skygold Ventures is a Canadian junior mining company delineating a large bulk tonnage gold deposit at Spanish Mountain in central British Columbia, Canada. Skygold is in the process of updating its Spanish Mtn. NI 43-101 gold resource estimate of 1.75 million ounces measured and indicated and 100,000 ounces inferred. The company also has three additional early stage sediment hosted gold (SHG) properties located on the same developing gold belt as Spanish Mtn. This area hosts numerous gold placer operations but until now has never been recognized for its hard rock potential. Skygold has commenced geological mapping, trenching and initial drill programs on the additional properties.

Company: Smartheat, Inc. Ticker Symbol & Exchange: SMHT (OTC BB) Investor Relations Contact: Ms. Huajun Ai Investor Relations Contact Phone: 86 24-25197699 Web: www.smartheatinc.com

Date of Presentation: 11/10/2008 9:55AM

SmartHeat is the leading publicly traded U.S. company operating in the highly profitable plate heat exchanger market in China. Our "green" plate heat exchanger (PHE) technology helps reduce fossil fuel related costs and pollution by capturing and recycling waste heat. Overall, industries using our products and technology consume less coal thereby lowering their CO2 emissions. As the developer of 5 key patents across our product lines, we are poised to continue the expansion of our operations in China's heat transfer industry, a market currently estimated at approximately $2.4 billion dollars with double digit annual growth.

Company: Solar Power, Inc. Ticker Symbol & Exchange: SOPW OTCBB Investor Relations Contact: HC International, Inc. Investor Relations Contact Phone: Ted Haberfield, 760-755-2716 Web: www.solarpowerinc.net Date of Presentation:

11/12/2008

Founded in 2005, Solar Power, Inc. is a vertically integrated solar energy solution provider offering the North American commercial and public sector building markets a complete solution through a single brand. The company's Yes! Solar SolutionsTM subsidiary provides the U.S. small- to mid-sized business and residential market segments with turnkey PV solar systems through a growing retail franchise network. Throughout Europe and Asia, the company sells its products direct to distributors and turnkey solutions providers. Solar Power, Inc. operates from its Roseville, California headquarters.

Company: SOYO Group Inc. Ticker Symbol & Exchange: OTCBB: SOYO Investor Relations Contact: Craig H. Bird Investor Relations Contact Phone: CHBird@segue.biz, (215) 392-4981 Web: http://www.soyo.com/ Date of Presentation:

Tuesday, November 11th

SOYO Inc. is an innovative provider of consumer electronics and IT products such as LCD Monitors, LCD HD Televisions, Bluetooth Devices, Portable Storage, and Home Theater Furniture products and services. Headquartered in Ontario, California, with additional sales offices in Latin America, SOYO sells its products through an extensive network of authorized retailers, distributors, resellers, system integrators, VARs, and ecommerce web sites. Products are sold under the SOYO, Dragon, Onyx, Dymond, Honeywell, Le Vello, and Prive brand names. For more information, please visit http://www.soyo.com.

For information on the Honeywell Consumer Electronics product lines, please visit www.honeywellce.com.

Company: Stem Cell Therapeutics Corp.

Ticker Symbol & Exchange: SSS TSX Venture Investor Relations Contact: Chloe Crampton Investor Relations Contact Phone: (403) 245-5495 Web: www.stemcellthera.com Date of Presentation:

11/12/2008

Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells.

SCT's programs aim to repair neurological function lost due to disease or injury. SCT's lead clinical program REGENESIS, currently in Phase IIb, targets the treatment of stroke by repurposing approved and clinically well defined drugs. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, ALS.

Company: SUNESIS PHARMACEUTICALS, INC. Ticker Symbol & Exchange: SNSS Investor Relations Contact: Monique Greer Investor Relations Contact Phone: (415) 946-1075

Web: www.sunesis.com Date of Presentation: November 12, 2008 @ 2:00 p.m.

Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. Voreloxin is currently being evaluated in both frontline and relapsed/refractory acute myeloid leukemia and in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

Company: Syntaxin Ltd Investor Relations Contact: Tim Pearce Investor Relations Contact Phone: +44 1235 552112 Web: www.syntaxin.com

Date of Presentation: November 12th

Syntaxin is a biopharmaceutical company that designs and develops novel drugs for the treatment of chronic diseases that act by controlling cell secretion.

Cell secretion plays an important role in the development of numerous diseases, including respiratory, endocrine, inflammatory and metabolic disorders, certain cancers, as well as chronic pain.

Syntaxin's proprietary technology enables the generation of novel therapeutic proteins with broad applicability across these major disease areas.

Syntaxin's strategy is to develop these novel biologic drugs that control cell secretion, a completely new approach to addressing major markets, and to focus on respiratory, endocrine and inflammatory disorders within its own pre-clinical development pipeline.

Company: Targeted Genetics Corporation Ticker Symbol & Exchange: TGEN:Nasdaq Capital Market

Investor Relations Contact: Stacie D. Byars; WeisComm Partners Investor Relations Contact Phone: 415-946-1072 Web: www.targen.com Date of Presentation: November 11th, 2008

Targeted Genetics Corporation develops and commercializes innovative, targeted, molecular therapies based on its proprietary DNA delivery platform, Adeno-Associated Virus (AAV), which can deliver DNA capable of encoding interfering RNA molecules such as miRNA or shRNA, or therapeutic proteins.

First to bring AAV vectors into the clinic, TGC has the deepest experience in the development, large-scale manufacture, and clinical trial experience using AAV. This experience has allowed the company to build numerous partnerships and alliances resulting in a diverse pipeline of clinical candidates for inflammatory arthritis, HIV vaccines, congenital blindness (LCA), congestive heart failure and preclinical candidates for Huntington's disease.

Company: TechPrecision Corporation

Ticker Symbol & Exchange: TPCS.OB, OTCBB Investor Relations Contact: Mr. Crocker Coulson Investor Relations Contact Phone: 646 213 1915 Web: www.techprecision.com Date of Presentation: Wednesday, November 12, 2008

TechPrecision Corporation, through its wholly-owned subsidiary Ranor, Inc., manufactures large scale metal fabricated and precision machined components and equipment used in a variety of markets including: alternative energy, medical, nuclear, defense, industrial and aerospace. The Company is one of a few end-to-end solutions providers with the ability to engineer the requisite tooling and the entire manufacturing process for each respective production program, fabricate, machine, assemble, test and deliver large scale projects with tight tolerance levels. TechPrecision is one of the few manufacturers in the U.S. with American Society of Mechanical Engineers (ASME) Certifications and Authorizations, which allow the design and construction of commercial nuclear equipment, and nuclear storage and shipping equipment.

Company: ThromboVision, Inc. Investor Relations Contact: Sally I Evans, APR Investor Relations Contact Phone: office: 713-660-7990; mobile: 713-557-2461 Web: www.thrombovision.com Date of Presentation: 11/10/2008

ThromboVision, Inc. is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision seeks to provide easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis. The company's products -under development and not yet released to market -- will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors, especially those related to platelet function and antiplatelet drug therapy. The company has filed a 510(k) application with the FDA for its initial product, the ThromboGuideÂŽ (T-GuideÂŽ) platelet aggregation system. www.thrombovision.com

Company:

Tianyin Pharmaceutical Co., Inc. Ticker Symbol & Exchange: AMEX: TPI Investor Relations Contact: HC International, Inc. Investor Relations Contact Phone: Feng Peng, 917-558-7610 Web: www.tianyinpharma.com Date of Presentation: 11/11/2008

Based in Chengdu, China, Tianyin Pharmaceutical Co., Inc. is a primary manufacturer, marketer and supplier of modernized Traditional Chinese Medicine (TCM). Established in 1994, the Company develops and manufactures a diversified portfolio consisting of 32 branded, cost-competitive modernized TCMs and 4 generic western medicines addressing a number of indications through its two GMP-certified manufacturing facilities and sells its products through an extensive nationwide distribution network managed by over 720 salespeople. Tianyin possesses a strong R&D platform supported by partnerships with leading Chinese academic institutions and has produced an extensive pipeline of 48 products in various stages of the approval process.

Company: Titan Pharmaceuticals, Inc. Ticker Symbol & Exchange: TTP Investor Relations Contact: Robert E. Farrell Investor Relations Contact Phone: (650) 244-4990 Web: www.titanpharm.com Date of Presentation: 11/10/2008

Titan Pharmaceuticals, Inc. (AMEX: TTP) is focused primarily on the late-stage development and commercialization of innovative treatments for central nervous system disorders. Probuphine, which utilizes Titan's proprietary ProNeura long term drug delivery technology, has demonstrated positive results in Phase III testing for the treatment of opiate addiction. The Company is also planning to develop this validated sustained drug delivery technology for other potential treatment applications in which conventional treatment is limited by variability in blood drug levels and poor patient compliance. Products based on ProNeura technology can provide controlled drug release on an outpatient basis over extended periods of up to 6-12 months. Titan also has two other products, gallium maltolate and DITPA, in earlier stages of development.

Company: TMNG Global Ticker Symbol & Exchange: TMNG: NASDAQ Investor Relations Contact: Corey Kinger Investor Relations Contact Phone: 212.986.6667 Web: www.tmng.com Date of Presentation: 11/11/2008

TMNG Global provides strategy and management consulting, software solutions, and other products and services, to more than 1,200 converging communications, entertainment, media and technology companies and financial services firms worldwide. The company is headquartered in Overland Park, Kansas, with offices in Boston, Chicago, London, New York, Shanghai and Washington, D.C.

TMNG tackles complex business problems and propels clients to profitable growth, optimal performance and sustainable competitive advantage.

TMNG Global assists clients in addressing transformational issues.

TMNG Global is singularly focused on helping clients improve their bottom line performance, whether by designing new strategies, optimizing organizations and processes, or implementing new systems, operations, products and services.

Company: Tongxin International, Ltd. Ticker Symbol & Exchange: NASDAQ: TXIC Investor Relations Contact: HC International, Inc. Investor Relations Contact Phone: 914-669-5340 Web: www.hntx.com Date of Presentation: 11/11/2008

Tongxin International Ltd. is a company focusing on China's fast-growing commercial vehicle market throught its initial combination of its wholly owned subsidiary, Hunan Tongxin Enterprise Ltd. It is the largest independent OEM supplier of Engineered Vehicle Body Structures ("EVBS") in China. The Company is capable of providing EVBS for both the commercial vehicle and light vehicle

market segments, in addition to designing, fabricating and testing dies used in the manufacturing process. Tongxin services more than 130 commercial vehicle manufactures in China and select export markets. Tongxin International has agreements in place to acquire Meihua Bus, a passenger bus manufacturer and a strategy to arcquire related automotive parts manufacturers in the near term.

Company: Ukrzernoprom Agro LLC Ticker Symbol & Exchange: Frankfurt: 4GW1 GR Investor Relations Contact: Inna Dekhtiar Investor Relations Contact Phone: 380 44 499 32 40 Web: www.uzp-agro.com.ua Date of Presentation: November 11, 9:30-10:55

Ukrzernoprom Agro is one of the leading crop raising companies in Ukraine. Growing and selling crops, wheat, rapeseed, barley, sunflower seed and corn is the Company's main line of business. It operates on more than 100 thousand hectare of fertile land.

Ukrzernoprom Agro tripled the previous year's production and harvested more than 240 thousand tons of grain-crops in 2008. Its yields are usually 25-35 % higher than average yields in Ukraine owing to use of new technologies, state-of-the-art land cultivation methods and energy saving technilogies. Ukrzernoprom Agro is the only Ukrainian crop growing company certified according to ISO 9001:2000 standards.

Company: Uranerz Energy Corporation Ticker Symbol & Exchange: AMEX and TSX: URZ Investor Relations Contact: Dennis Higgs Investor Relations Contact Phone: 604-689-1659 Web: www.uranerz.com Date of Presentation: 11/10/2008

Uranerz Energy Corporation is a pure-play uranium company focused on production. Members of the Uranerz management team have specialized expertise in the in-situ recovery ("ISR")

uranium mining method. Uranerz controls approximately 122,500 acres in the Pumpkin Buttes Uranium Mining District of the central Powder River Basin ("PRB") of Wyoming, U.S.A., an area well-known for hosting uranium-mineralized roll fronts often amenable to ISR mining techniques.

Uranerz has submitted federal and state mining applications to build and operate its Nichols Ranch ISR Uranium Complex. Upon receipt of required regulatory approvals, Nichols Ranch will host the main processing facility and also service the Company's planned future satellite plants in the PRB.

External Validation: Denison Mines Corp. strategic investment - owns 9.9% of Uranerz.

Company: Vaxin Inc. Investor Relations Contact: Bill Enright Investor Relations Contact Phone: enright@vaxin.com, 205-909-3751 Web: www.vaxin.com Date of Presentation: 11/12/2008

Vaxin is a clinical stage vaccine development company with innovative, single-dose, needle-free, cell-culture manufactured product candidates. Our lead indication is Influenza where we have shown proof of principle in people with a safe and well tolerated nasally administered seasonal vaccine that had a significant immune response in healthy volunteers. We are currently enrolling volunteers in a nasally administered Ph I pandemic vaccine (H5N1) study.

Vaxin's pipeline includes pre-clinical programs in anthrax, where we have shown 100% protection against lethal Ames spore challenge in two animal models and Alzheimer's disease vaccines. We also are developing several animal health vaccines, including an influenza vaccine delivered in ovo and an immunocontraceptive vaccine.

Company: Victory Nickel Inc. Ticker Symbol & Exchange: Toronto, symbol NI Investor Relations Contact: Sean Stokes Investor Relations Contact Phone: 416-363-8527

Web: www.victorynickel.ca Date of Presentation: Nov. 11

Victory Nickel Inc. is a Canadian company with three sulphide nickel deposits containing significant 43-101-compliant nickel resources.

Victory Nickel is focused on becoming a mid-tier nickel producer by developing its existing properties, Minago and Mel in Manitoba, and Lac Rocher in northwestern Quebec, and by evaluating opportunities to expand its nickel asset base. Victory Nickel also owns approximately 84% of the outstanding shares of Independent Nickel Corp. ("Independent") (TSX:INI).

Company: VirtualScopics, Inc. Ticker Symbol & Exchange: VSCP Investor Relations Contact: Molly Henderson Investor Relations Contact Phone: 585.249.6231 Web: www.virtualscopics.com Date of Presentation:

11/12/2008

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. The Company has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with its industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.

The Company is currently working with 12 of the leading 15 pharmaceutical, biotechnology and medical device companies in the world.

Company: Vitae Pharmaceuticals Investor Relations Contact: Lilian Stern Investor Relations Contact Phone: 212-362-1200 Web: www.vitaepharma.com Date of Presentation: 11/11/2008

Vitae Pharmaceuticals is an emerging pharmaceutical company with a unique, powerful structure based drug design engine and a rapidly maturing portfolio of high value discovery programs. Vitae's lead program is in renin inhibition for cardiovascular disease, and is expected to enter the clinic in 2009. Vitae also has an 11-beta HSD1 diabetes / metabolic syndrome program, partnered in 4Q 2007 with Boehringer-Ingelheim, and an early but rapidly progressing BACE program for Alzheimer's.

Vitae's goal is to discover and develop innovative new medicines with best in class potential in important therapeutic areas such as cardiovascular and metabolic disease, CNS and inflammation.

Company: VIVALIS Ticker Symbol & Exchange: VLS.PA Investor Relations Contact: Steve Grobet / Emmanuel Huynh Investor Relations Contact Phone: 33 (0) 1 44 71 94 91 Web: www.vivalis.com Date of Presentation: 11/10/2008

Vivalis (NYSE-Euronext: VLS.PA) is a biopharmaceutical company that provides innovative cell-based solutions for the industrial production of viral vaccines and therapeutic proteins and develops drugs to prevent and treat viral diseases.

Vivalis offers research and commercial licenses for its EB66ÂŽ cell line, to pharmaceutical and biotechnology companies for the production of viral vaccines and therapeutic proteins. Vivalis receive up front, milestones and royalties payments on its licensees net sales. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Schering Plough, Bavarian Nordic, Acambis, Kaketsuken, CSL, Merial and SAFC Biosciences,

Company: WaferGen Biosystems Ticker Symbol & Exchange: OTCBB: WGBS Investor Relations Contact: Rachel Lipsitz Investor Relations Contact Phone: 858-4499575 Web: www.wafergen.com

Date of Presentation: 11/10/2008

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research.

Company: WorldWater & Solar Technologies Ticker Symbol & Exchange: OTC BB: WWAT Investor Relations Contact: Chris Witty Investor Relations Contact Phone: 646-438-9385 Web: www.worldwater.com

Date of Presentation: 11/12/2008

WorldWater & Solar Technologies Corp. is a full-service solar electric engineering, design and water management company with unique, high-powered and patented solar technology solutions to a broad spectrum of electricity and water supply problems. Earlier in 2008, WorldWater merged with ENTECH, Inc., a high-technology solar energy company specializing in patented solar concentrating and PVT (thermal) systems. ENTECH's systems can produce electrical output, a combination of electricity and thermal energy, or thermal energy alone. Commercial applications vary in size from one kilowatt remote power units to large, multi-megawatt utility power plants. For more information go to www.worldwater.com.

Company: ZBB Energy Corporation Ticker Symbol & Exchange: ZBB Investor Relations Contact: SMH Market & Liquidity Service Investor Relations Contact Phone: Joanne Verkuilen, 212-893-1122 Web: www.zbbenergy.com

Date of Presentation: 11/10/2008

ZBB Energy Corporation (ZBB) provides clean energy storage solutions based on proprietary zinc rechargeable energy storage technology that addresses requirements in multiple markets such as alternative energy applications, large electrical utilities and green residential and commercial architecture. A developer and manufacturer of its modular, transportable and environmentally friendly Zinc Energy Storage Systems ("ZESS'), ZBB Energy was founded in 1998 and is headquartered in Wisconsin with offices located in Perth, Australia.

Company: Zelos Therapeutics, Inc. Investor Relations Contact: Alan Roemer, CFO Investor Relations Contact Phone: (610) 825-1468 Web: http://www.zelostherapeutics.com Date of Presentation: 11/10/2008

Zelos Therapeutics is developing therapeutics for the treatment of

osteoporosis and other bone diseases. Our lead clinical compound, ZT-031, is a parathyroid hormone (PTH) analog that has demonstrated increases in bone formation. ZT-031 is entering Phase 3 registration studies and has the potential to become a leading therapy to treat osteoporosis in the growing PTH market. In addition, Zelos Therapeutics is evaluating potential orthopedic uses of ZT-031's bone formation properties for fracture repair, trauma and use as a surgical adjunct.

Company: ZIOPHARM Oncology, Inc. Ticker Symbol & Exchange: Nasdaq: ZIOP Investor Relations Contact: Tyler Cook Investor Relations Contact Phone: (617) 259-1982 Web: www.ziopharm.com Date of Presentation: 11/11/2008

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on the development of three

clinical programs for multiple indications. Palifosfamide (ZIO-201) is a novel molecule that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, testicular cancer, lymphoma and other cancers. Indibulin (ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Darinaparsin (ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. For further information about ZIOPHARM visit www.ziopharm.com.